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ABSTRACT
Falls are the leading cause of unintentional injuries in older people, and hip fractures are
among the most serious consequences of falls. Most falls have a multifactorial etiology with
drug-related adverse effects being one of the contributors that may increase the risk of falling.
   The goals of this thesis work were to review recent original publications concerning
medications as a risk factor for falls, to determine the overall incidence and recurrence rate of
hip fractures, and to assess the effects of hip fractures on the utilization of inpatient care and
mortality.
Twenty nine original articles met the inclusion criteria for the systematic review.
Benzodiazepines, antidepressants, and antipsychotics were associated with an increased risk
of  falls  in  older  people.  However,  randomized  controlled  trials  were  rare,  and  many  of  the
observational studies had methodological limitations.
   The incidence of hip fractures in Central Finland in 2002-2003 was determined using
hospital registers and medical records. The results were compared with those of an earlier hip
fracture study conducted in the same area. The hip fracture patients and the general
population living in the study area were followed up for hospitalizations and cases of death.
   In 2002-2003, 597 hip fractures occurred in Central Finland. The number was 70% higher
than in 1992-1993, and the age adjusted incidence of hip fractures increased in both genders.
The median length of perioperative stay in the Central Finland Hospital was 7 days, and after
that the majority of hip fracture patients were transferred to primary care wards of their home
municipalities. The cumulative incidence of second hip fractures was 5% at one year after the
initial fracture and 8% at two years.
   Of the ?70-year-old hip fracture patients, 8% died during their primary stay in the Central
Finland Hospital, 15% died within the first postfracture month and 33% in the first
postfracture year. The first-year mortality ratio between the hip fracture patients and the
same-aged general population was 2.9.
   The rate ratio of age-adjusted hospital days per person-year between the hip fracture group
and the general population was 1.3 in the prefracture year, 6.9 in the first postfracture year
and 3.6 in the second postfracture year. Throughout the 3-year period, the number of hospital
days due to injuries was higher in the hip fracture group than in the general population. An
excess of hospital days was also seen in six other diagnostic classes in the first and in four
diagnostic classes in the second postfracture year.
Based on the incidence rates, and mortality and morbidity following hip fracture, more
attention should be paid to prevention of falls and fall-related fractures. There is also room
for improvement in the perioperative management of hip fracture patients. After surgical
treatment, centralized multidisciplinary care and rehabilitation could lead to better outcomes.
As a part of fall and hip fracture prevention, regular medication reviews are important
National Library of Medicine Classification: QV 77.2, WA 288, WE 855
Medical Subject Headings: Accidental Falls; Aged; Central Nervous System Agents/adverse
effects; Finland; Hip Fractures/epidemiology; Incidence; Osteoporosis; Psychotropic
Drugs/adverse effects; Risk Factors
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1. INTRODUCTION
As life expectancy increases older people will make up a large and rapidly growing
percentage of the Finnish population. Aging is related to several physiological
changes and decline in health, including for example reduced muscle and bone
strength, gait and balance problems and visual deficits which can increase risk for
falling and fall-related injuries.
   More than one third of people aged 65 or over fall each year, and approximately
one in ten falls results in a serious injury (1). Hip fractures are one of the most
devastating and costly consequences of falls (2). The lifetime risk of hip fracture
varies from 11 to 23% for women and 3 to 11% for men (3). In Finland, over 7000
hip fractures occur annually (4,5).
Many of the risk factors for falls and hip fractures are modifiable and reversible.
However, screening and prevention of falls and fall-related injuries is often sub-
optimal (6-8). Health care professionals are more experienced at managing discrete
diseases than managing multifactorial conditions, such as falling. Maybe assessing
the risk of falls has not considered being physician’s work. Even in the case of fall-
related injuries, attention is often paid to the treatment of the present trauma only,
while forgetting its etiology and strategies to prevent future events. Therefore well-
established care pathways are needed to improve medical management of older
people at risk of falls or with hip fracture.
   Providing current information, and from local settings, may be a worthwhile
strategy for raising awareness among clinicians and decision-makers to promote falls
prevention and better care of older people with hip fracture. Against this background,
a population-based study on epidemiology of hip fractures was performed in Central
Finland.
   The aims of this thesis work were to determine incidence and recurrence rate of hip
fractures, mortality after hip fracture, and the impact of hip fractures on the inpatient
care utilization. Furthermore, a systematic review on recent publications regarding
medication use and risk of falls and hip fractures was conducted.
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2. REVIEW OF THE LITERATURE
2.1 Epidemiology of falls
Though  fall  accidents  occur  at  all  ages,  the  incidence  and  severity  of  falls  increase
with age. The majority of falls have a multifactorial etiology, and with advancing age,
the significance of intrinsic risk factors, such as morbidity, increases. Medications
may also increase risk of falls. Morbidity, use of medicines and adverse drug
reactions all become more common in older age. Yet, few of the risk factors for falls
are as potentially preventable or reversible as medication use. The section
“Epidemiology of falls” deals with literature on research methodology, and incidence,
risk factors and consequences of falls.
2.1.1 Definition and ascertainment of falls
A crucial methodological issue in epidemiological research is to provide a clear and
preferably a standardized definition of the outcome. Thus studies on falls should
determine events that are considered as falls. One of the most commonly used
definitions of a fall was provided by the Kellogg group (9). A fall was defined as
“unintentional coming to the ground or some lower level and other than sustaining a
violent blow, loss of consciousness, sudden onset of paralysis as in stroke or an
epileptic seizure”. If falls due to cardiovascular and neurological causes (e.g.
dizziness, syncope, and orthostatic hypotension) are also addressed, the definition of
the Prevention of Falls Network Europe (ProFaNE) collaborators is more suitable.
They define a fall as an unexpected event in which the participant comes to rest on
the ground, floor, or lower level (10). The definition is comparable to that published
by the World Health Organization (WHO): a fall is an event which results in a person
coming to rest inadvertently on the ground or floor or other lower level (11). Above
all, the outcome definition should be clear and understandable for the outcome
observers, i.e. for participants in community-based studies and for nursing staff in
institution-based studies.
17
Studies focusing on fall-related injuries should also provide a definition for the term
injury. The WHO's International Classification of Diseases (ICD) defines injuries and
their occurrence mechanisms (12). These codes and definitions are often used in
studies focusing on fall-related injuries. Peripheral fractures account for the majority
of costs, morbidity and mortality generated by fall-related injuries, and therefore
registration of these accidents has been recommended (10,13).
   Another methodological issue is how the data on falls is gained. In the retrospective
studies, information on falls is based on recall. The participants are asked whether
and/or how many times they had fallen over a defined period, most often within past
12 months. It is questionable whether falls are remembered accurately over a
prolonged period (14). Utilizing a prospective study design provides a better basis for
the follow-up of falls. In community studies, participants should be asked to record
their falls. Then the data is collected by postal questionnaires (15,16), fall calendars
(17,18,19) or telephone interviews (20). Prospective daily recording of falls with a
minimum of monthly reporting is recommended by the ProFaNE collaborators (10).
Additional information about the circumstances of falls can be gained by attaching a
case-specific fall questionnaire to the fall calendar. In residential care settings,
prospective follow-up and systematic recording of falls by nursing staff is a
recommended and feasible method (15).
   Unfortunately, there is a considerable methodological heterogeneity in the studies
reporting falls. A systematic review of randomized controlled fall prevention trials
showed that the term fall was defined in one half (46/90) of the studies, and falls were
registered prospectively only in 39 of 90 trials (21).
2.1.2 Incidence of falls in community-dwelling older people
Approximately 30% of community-dwelling people aged 65 years or more fall at
least once a year (20,22,23), and 10 - 20% fall recurrently (19,22,24). Older people
with health problems and impairment in basic ADLs tend to fall more often.
Approximately 37% of those receiving home care reported they had fallen in the past
three months (25). The proportion of fallers increases also with age, being 40 - 50%
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in people aged 80 years or more (19,20). Furthermore, falls are more common in
older women than men (26-28). In Northern Finland, the overall incidence rate of
falls was 611 per 1000 person-years (py) in women and 368/1000 in men aged 70
years or over (23,29) .
   The incidence of falls may also vary between different ethnic and race groups,
though rigorous data from non-Caucasian populations is limited. Nine percent of 65
years old or older community-dwelling Japanese men and 19% of women reported
that they had fallen one or more times during the previous year (30). Among older
people residing in Hong Kong, the proportion of fallers was 20% (31), whereas
among Finns, it was 30% (23).
   The location of falls seems to be related to functional capacity, gender, and age. In
community-dwelling older people, about 50% of falls occurred in their homes or
immediate home surroundings, and the remaining falls were sustained in public
places or other people’s homes (32,33). Women were more likely than men to fall
inside the home (65% vs. 44%) (22). In women, the proportion of falls occurring at
home on a level surface increased with age (34). In general, indoor falls were
associated with frailty and limited mobility, and most of the falls occurred during
mornings or afternoons in situations where older people were undertaking their usual
daily activities (22,23). Additionally, the ambient temperature may have an impact on
the frequency of falls, and in some studies, seasonal variation in the incidence of falls
has been observed. Luukinen et al. found that the frequency of outdoor falls was
higher in periods of extreme cold (29).
2.1.3 Incidence of falls in institutional care facilities
The incidence of falls in institutional settings has been widely studied. The frequency
of falls is high among older people living in institutions. The rate of falling in
residential care populations has been reported to be two- to threefold that in
community-dwellers (23,28).
   Approximately 50% of nursing home residents fall at least once a year. In an early
prospective study performed in institutional care settings, the proportion of fallers
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was 42%; 30% in men and 46% in women (35). Thereafter, higher percentages have
been reported, ranging from 54% to 57% (36-38). Recurrent falls are also common.
Forty four percent of nursing home residents fell recurrently during a 7-month
observation period (39), and in two other studies, 40% to 56% of ambulatory
residents fell two or more times within six months (40,41). Furthermore, 54 recurrent
falls per 100 py were observed in an American nursing home population (42).
Rubenstein et al. summarized the findings from 16 studies and reported that the mean
annual incidence of falls in nursing homes was 1.5 falls per bed (range: 0.2 to 3.6
falls) (43).
   Inhospital falls are also common. During their hospital stays, 17% of patients fell in
an acute geriatric ward (44), and 14% of patients experienced one or more falls in a
geriatric rehabilitation hospital (45). In older patients undergoing stroke
rehabilitation, the rate of fallers was up to 39% (46-48).
2.1.4 Risk factors for falls
Causes of falls can be categorized to predisposing and precipitating factors, the
former representing long-term and the latter short-term risks (1). Another approach is
to define the risk factors as either intrinsic (e.g., lower extremity weakness, balance
disorders, functional and cognitive impairments, visual deficits) or extrinsic (e.g.,
polypharmacy, use of certain medications) and environmental factors such as poor
lightning, loose carpets, and lack of bathroom safety equipments (49). Furthermore,
the role of environmental risks can be supplemented with exposure to risk (50). Most
falls have more than one cause, and it is important to be aware of interactions and
synergism between the risk factors.
2.1.4.1 Age and gender
Age has been assessed as a potential risk factor for falls in many studies, and several
studies have shown that the incidence of falls increases with age (17,19,20,51-53). In
a systematic review of falls risk, age was addressed in 11 studies but it proved to be
an independent predictor of falls in four studies only (54). This is understandable
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because falls are generally considered to be a marker of frailty and decreased
mobility, both of which become more common with increasing age.
   In  addition  to  the  probability  of  falling,  age  is  associated  with  severity  of  falls.
Injurious falls become more common with advanced age (43,55,56). Furthermore, an
increasing long-term trend has been observed in the incidence of injurious falls (57).
Between 1970 and 1995 in Finland, the number of fall-induced injuries increased
more than could be explained merely by population aging. The increasing trend was
greatest in persons aged 80 years or older. The explanation behind this phenomenon
might be deterioration of bone strength and an increase in the incidence of falls.
Increased survival of ill and frail older individuals may also increase the frequency of
falls and fall-related injuries.
   Gender may have an impact on the risk of falling. It has been shown that women
fall more often than men (20,23,26,27,51,53,58). This has been explained by
women’s weaker muscle strength and greater visual field dependence, i.e. greater
reliance on visual input in maintaining balance (59). However, some studies have not
found any gender difference in the incidence of falls (17,19,22,60), or the difference
has been age dependent leveling off with advanced age  (20,23,53).
2.1.4.2 Gait and balance
The physiological systems that are involved in maintenance of stability decline with
age. Impairments in vision, vestibular system, peripheral sensation, muscle strength,
and integration of sensorimotor functions (e.g. reaction time) may predispose to falls.
In addition to age-related changes, many diseases (e.g. diabetes, musculoskeletal and
neurological diseases) may interfere and impair gait and balance control. The
association between visual impairment and increased falls risk has been shown in
several studies (61-66). Ganz et al. summarized findings of 15 studies that considered
gait or balance abnormalities and the risk of falling (54). In 10 of 15 studies, older
people  with  impaired  gait  or  balance  had  an  increased  risk  of  falls.  The  systematic
review by Rubenstein and Josephson assessed impacts of several factors on the risk of
falling (28). Table 1 summarizes the findings of their review. Gait deficits were
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related to falls in 10 of 12 studies and balance deficits in eight of 11 studies. Muscle
weakness was also strongly associated with falls.
Table 1. The most common risk factors for falls identified in 16 studies, findings are
based on univariate analyses. Adapted from Rubenstein and Josephson (28).
Risk factor Significant / Total a Mean
RR  / OR b  (range)
Muscle weakness 10 / 11 4.4 (1.5 to 10.3)
History of falls 12 / 13 3.0 (1.7 to 7.0)
Gait deficit 10 / 12 2.9 (1.3 to 5.6)
Balance deficit   8 / 11 2.9 (1.6 to 5.4)
Use of assistive device   8 / 8 2.6 (1.2 to 4.6)
Visual deficit   6 / 12 2.5 (1.6 to 3.5)
Arthritis   3 / 7 2.4 (1.9 to 2.9)
Impaired ADL   8 / 9 2.3 (1.5 to 3.1)
Depression   3 / 6 2.2 (1.7 to 2.5)
Cognitive impairment   4 / 11 1.8 (1.0 to 2.3)
Age > 80 years   5 / 8 1.7 (1.1 to 2.5)
a Number of studies with significant relative risk ratio or odds ratio /
   total number of studies addressing each risk factor
b Relative risk ratios or odds ratios calculated for studies
2.1.4.3 Medical conditions
Several medical conditions can contribute to the risk of falling. Cognitive impairment
and acute confusional states may increase the risk by influencing an older person’s
ability to appropriately deal with environmental hazards, and by causing behavioral
symptoms such as wandering and altering gait patterns (67,68). Several investigators
have reported that dementia is a strong and consistent risk factor for falls, especially
for injurious falls in older people (69). Falls related to cognitive impairment are of
particular concern in long-term care facilities, because the prevalence of dementia is
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high in these populations. For example in Finland, over 90% of older people living in
long-term care institutions are demented (70).
   In addition to dementia, some other neurological conditions are also associated with
falls in older people. There is strong evidence of increased risk of falls among persons
with a diagnosis of stroke, and a probable risk in those with Parkinson’s disease or
peripheral neuropathy (69). These conditions are capable to decrease muscle strength
and impair gait and balance control.
   Furthermore, depression, which is common in older people (71,72) is associated
with falls (28,73). Mechanisms through which it increases the risk of falls have not
been fully evaluated. Decline in physical activity and muscle strength is a possible
explanation, but the use of antidepressant medications may also have a role.
   Musculoskeletal diseases have been related to falls. Inflammatory or degenerative
joint  disease  was  found  to  be  a  risk  factor  for  falls  in  three  of  seven  studies  in  the
systematic review of Rubenstein and Josephson (Table1) (28). Osteoarthritis is the
commonest  cause  of  musculoskeletal  disability  in  older  people  (74).  It  leads  to
structural deformity, decreased range of motion and pain of the affected joint. People
with hip and knee osteoarthritis tend to walk and exercise less and therefore often
suffer wasting of lower extremity muscle groups. Joint deformity also impairs
proprioception. Therefore quite logically, reduced knee extension strength and
increased postural sway were identified as significant predictors of falls in older
people with lower limb osteoarthritis (75).
   A strong link between orthostatic hypotension and falls has not been documented
(54). This can be of an intermittent nature of orthostatic hypotension, i.e. it is not
necessarily present all the time and the diagnosis is easily missed if orthostatic blood
pressure is measured only once. The association may also be stronger to underlying
cause of orthostatic hypotension than to the reaction itself. For example Parkinson’s
disease and diabetes can cause orthostatic hypotension through autonomic
neuropathy, but both of these diseases can also have other manifestations that are fall-
risk-increasing. Similarly, antipsychotics may cause orthostatic hypotension but also
extrapyramidal side effects that increase the risk of falling. Some falls have a
cardiovascular etiology. Especially in case of syncopal or unexplained falls, the
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underlying cause can be cardiovascular, such as carotid sinus hypersensitivity,
atrioventricular block, or sick sinus syndrome (49, 76, 77).
   Lower urinary tract symptoms and incontinence may contribute to the risk of falling
in older people (24,78-81). Falls related to incontinence are generally thought to
result from loss of balance when rushing to the toilet. However, there is debate about
whether incontinence is a primary cause of falls or is it simply a marker of
generalized physical frailty (82).
2.1.4.4 Medications
The aging process is associated with changes in pharmacokinetics and
pharmacodynamics (83) which may contribute to the risk of falling. Age-related
changes in the body composition have effects on the drug distribution. The volume of
distribution of lipid-soluble drugs (e.g. many the psychotropic agents) increases, and
the elimination half-life and duration of action of these drugs tend to be prolonged.
Decrease in the total body water content leads to higher concentrations from given
amounts of water-soluble drugs, such as digoxin and certain beta-blockers.
Bioavailability of drugs tends to increase with age due to decreasing first pass
metabolism, whereas hepatic biotransformation tends to decline. Renal function and
the excretion of drugs decline with age, especially those eliminated predominantly by
the kidneys, e.g. many angiotensin converting (ACE) inhibitors, metformin, digoxin.
Furthermore, changes in tissue sensitivity and receptor affinity may affect drug
responses, for example adverse reactions related to centrally acting medications (e.g.
sedation, dizziness, extrapyramidal symptoms) become more prevalent with age.
   With regard to falls, psychotropic drugs (i.e. benzodiazepines, antidepressants and
antipsychotics) are the most often researched medication group. Leipzig et al.
conducted a systematic review and meta-analysis on psychotropic drugs and falls
(84). Their literature search covered studies published through 1966 to 3/1996, and 43
original articles were included in the review. The meta-analysis on the use of any
psychotropic drug covered 20 studies and the pooled odds ratio (OR) for one or more
falls was 1.73 [95% confidence intervals (CI): 1.52 to 1.97]. A total of 13 studies
24
provided data on benzodiazepines. The use of any benzodiazepine was associated
with an increased risk of falls, the pooled OR was 1.48 (95% CI: 1.23 to 1.77). Short-
acting benzodiazepines were no safer than the long-acting benzodiazepines.
Antidepressants were addressed in 27 studies. The use of any antidepressant increased
the risk of falls, the pooled OR was 1.66 (95% CI: 1.41 to 1.95). The OR for tricyclic
antidepressants (TCAs) was 1.51 (95% CI: 1.14 to 2.00). Only one study paid
attention to selective serotonin reuptake inhibitors (SSRI), and the percentage of
fallers was larger among the SSRI than TCA users (85). For antipsychotics the pooled
OR was 1.5 (95% CI: 1.25 to 1.79), this analysis based on 22 studies.
Table 2. Pooled odds ratios for one or more falls associated with the use of cardiac
and analgesic drugs. Adapted from Leipzig et al (86).
Treatment Number of studies OR (95% CI)
Cardiac drugs:
   Any diuretic 26 1.08 (1.02 to 1.16)
   Thiazides 12 1.06 (0.97 to 1.16)
   Loop diuretics 11 0.90 (0.73 to 1.12)
   Digoxin 17 1.22 (1.05 to 1.42)
   Nitrates 14 1.13 (0.95 to 1.36)
   Beta-blockers 18 0.93 (0.77 to 1.11)
   Calcium channel blockers 13 0.94 (0.77 to 1.14)
   ACE inhibitors 10 1.20 (0.92 to 1.58)
   Centrally acting antihypertensives 11 1.16 (0.87 to 1.55)
   Type IA antiarrythmics 10 1.59 (1.02 to 2.48)
Analgesic drugs:
   Narcotic analgesics 13 0.97 (0.78 to 1.20)
   Nonnarcotic analgesics 9 1.09 (0.88 to 1.34)
   Nonsteroidal anti-inflammatories 13 1.16 (0.97 to 1.38)
   Aspirin 9 1.21 (0.80 to 1.57)
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Associations between the use of cardiac or analgesic drugs and falls were examined
in another systematic review and meta-analysis by Leipzig et al. (86). The results on
cardiac drugs are presented in Table 2. Digoxin, type IA antiarrythmics, and diuretics
were associated weakly with falls in older people, whereas no association was found
between the use of analgesics and falls. Fourteen studies provided data on multiple
medication use and falling. Use of more than three or four drugs was associated with
an increased risk of single falls in 6/14 studies and with recurrent falls in 4/5 studies.
   Studies on medication use and falls published in 1996 – 2004 are evaluated in our
systematic review (Study 1). Table 3 shows summary of studies on psychotropic drug
use and falls published in 2005 - 2008. In addition to the studies referred above, falls
have been associated with the use anxiolytic, anti-Parkinson, sedative/hypnotic and
diabetes medications in hospital settings (87,88), but younger patients were also
included in these studies. Few studies on medication classes other than psychotropics
were found. Nitrates and anti-diabetic drugs were associated with falls in community-
dwelling older people (31,89) and ACE inhibitors in nursing home residents without
dementia (90). Polypharmacy was related to an increased risk of falls in a Dutch
population (91), in women with a recent fracture (92), and in nursing home residents
with dementia (90).
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Table 3. Summary of studies published in 2005-2008 and reporting on the use of psychotropic drugs and risk of falls in older people
Reference Setting Number and
age of subjects
Association between  psychotropic drugs and falls
Risk increase No association
Hien et al. 2005 (93) RC, NH N= 2005
Age ? 65
 antidepressants, olanzapine risperidone, typical antipsychotics,
sedatives/anxiolytics
Landi et al. 2005 (25) CD N= 2854
Mean age = 77
 antipsychotics,
 benzodiazepines
antidepressants, benzodiazepine like
hypnotics
Avidan et al. 2005 (94) NH N= 34,163
Age ? 65
hypnotics
Souchet et al. 2005 (89) CD N = 67464
Mean age = 76
 benzodiazepines, TCA and
 SSRI antidepressants
Lee et al. 2005 (31) CD N= 4000Age ? 65
 psychotropics
Ziere et al. 2006 (91) PB N= 6928Mean age = 71
 benzodiazepines
Cooper et al. 2007 (95) NH N= 177Mean age = 84
 number of psychotropic drugs
Pariente et al. 2008 (96) CD N= 3777
Age ? 65
 benzodiazepines
Kerse et al. 2008 (97) CD N = 20636
Age ? 60
 any antidepressants, SSRIs antipsychotics, anxiolytics, hypnotics
CD = community-dwelling, NH = nursing home, PB = population-based, RC = residential care
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2.1.4.5 Environmental factors
Most home environments contain factors that may contribute to falling (98), e.g.
slippery floor surfaces, loose carpets, upended carpet edges, obstructed walkways, too
high  or  low  set  shelves  or  cupboards,  stairs,  and  unsafe  bathroom  surroundings.
Environmental factors associated with outdoor falls are for example sloping, slippery,
obstructed,  or  uneven  pathways,  ramps  and  stairways,  certain  whether  conditions,
crowds of people, and lack of places to rest. However, it is less clear to what extent
these hazards are causally related to falls. For example two case-control studies
reported that there were differences in the prevalence of home environment risk
factors between fallers and non-fallers (99,100), but in three studies the prevalence of
hazards was similar in both groups (101-103). The literature suggests that in addition
to the existence of hazards, an interaction to an older person’s physical or cognitive
abilities, i.e. coexisting impairment, is needed.
   Level  of  activity  seems  to  play  a  role,  too.  In  two  prospective  cohort  studies  on
environmental hazards and falls, the subjects were classified as either vigorous or
frail (104,105). Though falls were more frequent among frail persons, environmental
hazards, outdoor hazards in particular, were more likely to contribute falls in vigorous
older people than in the frail ones. It probably is more likely that vigorous people go
outside, even in worse weather conditions, have outdoor activities, and do more
hazardous housekeeping tasks than frail persons.
   Furthermore, external causes such as poor footwear (106) and inappropriate
spectacles (107) are risk factors for falls. The role of assistive devices is ambiguous.
Use of a walking aid has been associated with falls (28), but this does not mean that
the device causes falls. Instead, it may simply be a marker of gait and balance
problems.
2.1.4.6 History of falls and fear of falling
History of falls is a strong predictor of future falls. In the systematic review of Ganz
et  al.,  each  of  the  11  studies  reporting  on  history  of  falls  found  a  statistically
significant relationship to future falls (54). This is in concordance with the results of
systematic review and meta-analysis by Rubenstein and Josephson, in which a
previous fall predicts future falls in 12 of 13 studies (Table 1) (28).
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Fear of falling was also associated with future falls (24,108), mostly because those
who  are  fearful  of  falling  tend  to  restrict  or  eliminate  their  social  and  physical
activities (24,109). This risk factor seems to be interrelated with the history of falls:
falls cause fear of falling and visa versa.
2.1.5 Consequences of falls
Depending on the population studied and definition of outcome, from 20% up to 60%
of falls in older people result in some sort of injury, and approximately 10% of falls
cause major injuries (28,43,56,110-112). Falls are the leading cause of injury-related
admissions to hospital, and they account for 10-20% of visits to emergency
department and 4-6% of hospitalizations in older people (113-117).
   Approximately 5% of falls in older people lead to fracture (56,65,118). Though
fracture of the hip occurs only in around 1% of all fall incidents (114), almost all hip
fractures (97%) in older people are fall-induced (119). In terms of morbidity,
disability,  mortality,  and  costs,  a  fracture  of  the  hip  is  one  of  the  most  serious
consequences of falls (2).
   Falling is associated with subsequent admission to a nursing home (120-122).
Tinetti et al. assessed all nursing home placements in a large prospective cohort of
older people (123). They found an independent relation between falls and long-term
care placements: one noninjurious fall represented threefold, recurrent noninjurious
falls fivefold, and injurious falls a tenfold risk increase. They concluded that along
with other risk factors, falls, particularly frequent and injurious ones contribute
strongly to the decision by older persons and their families to pursue placement in a
nursing facility.
   Injuries are the fifth leading cause of death in older adults, and most of these fatal
injuries are related to falls (1,57,124). Kannus et al. examined trends in fall-induced
deaths among ?50-year-old Finns (125). In 2002, the total number of fall-induced
deaths was 1039, and the age-adjusted rates of fall-induced deaths were 55.4/100 000
and 43.1/100 000 for men and women, respectively. The incidence rate in men was
increasing, whereas in women, it stayed relatively stable between 1975 and 2002.
   In conclusion, falls in older people occur in every day life situations, and in most
cases, they are associated with more than one predisposing and precipitating factors.
Falls are the leading cause of unintentional injuries and constitute a significant health
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care cost through inflicting disabling conditions, hospital stays, and death. In terms of
morbidity and mortality, hip fracture is among the most serious consequences of falls.
2.2 Epidemiology of hip fractures
Hip fracture is a common, devastating, and often fatal, trauma in older people (2).
Lifetime risk of hip fracture is estimated to vary between 9% and 23% in women and
4% and 11% in men, depending on the population studied (3,126-128). Hip fractures
are rare before age of 50, but thereafter, the incidence increases exponentially with
advancing age (129,130). Therefore in many countries, the absolute number of hip
fractures is expected to rise as a consequent of population aging (131). Besides age,
female gender is also associated with higher rates of hip fracture (132). Epidemiology
of hip fractures has been widely studied during the past 20 to 30 years. The following
literature review deals with incidence, risk factors, and consequences of hip fractures.
2.2.1 Incidence of hip fractures
The worldwide number of hip fractures was estimated to be 1.26 million in 1990; 338
000 in men and 917 000 in women (133). In 2000, the estimated number was 1.62
million (134), and assuming no change in the age- and sex-specific incidences, the
projections for the years 2025 and 2050 were 2.6 and 4.5 million respectively (133).
The highest hip fracture incidences have been reported in Northern Europe,
Scandinavia in particular, North America and Australia (2,129,131).
2.2.1.1 Incidence of hip fractures in Finland
The Finnish national hospital discharge register has proved to be a useful data source
for studies on epidemiology of hip fractures (4,5,135,136-138). Based on the data of
this register, the total number and age-adjusted incidence of hip fractures increased
steadily in both genders between 1970 and 1997 (136,137). During the next five
years, the age-adjusted hospital admissions for fractures of hip showed leveling off
and stabilizing (4,138). Furthermore, a declining trend was observed by the end of the
year 2004, among women in particular (5).
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Among ?50-year-old Finns, the yearly mean number of first hip fractures was
reported to be 5618 in 2000-02 (138). In 2002, the age-adjusted incidence rates were
4.08 and 1.90 per 1000 py for women and men, respectively. In another Finnish
study, the estimated number of hip fractures was 7083 in 2004, and the adjusted
incidences were 4.12 per 1000 women and 2.23 per 1000 men (5). Discrepancies
between these results are mainly due to methodological issues; how to select and
evaluate  the  data  of  hospital  discharge  register.  In  addition,  the  populations  at  risk
differed. The standard populations of the studies based on different periods of time,
1998-2002 (138) vs. 1970-2004 (5).
   Some regional differences have been observed in the incidence of hip fractures in
Finland. Between 1998 and 2002, the incidence was highest in Helsinki and Central
Finland, and lowest in South Karelia, Southern Ostrobothnia and Kainuu regions
(138). Furthermore, the incidence trends differed between the regions. The age- and
sex-adjusted annual incidence of hip fractures increased in North and South Savo and
decreased in Helsinki and Kanta Häme during the five-year period. In other health
care districts, the incidences were stabile or fluctuating. In an earlier cross sectional
study, no statistically significant change was observed in the age-adjusted incidence
of hip fractures in Central Finland between the years 1982-83 and 1992-93 (139).
   Furthermore, hip fracture incidence rates between urban and rural populations have
been compared. The study of Lüthje et al. covered populations of Central Finland and
Kymeenlaakso health care districts in 1989 (140). The incidences between the urban
and rural populations did not differ statistically significantly in either of the districts.
   A slight seasonal variation in the incidence of hip fractures has been observed
(138,141-143), though the winter peak for hip fractures was relatively small
compared to that of the other peripheral fractures (143). This may be explained by the
fact that regardless of the season, the vast majority of hip fractures occur indoors
(22,142,144).
   Hip fracture incidence was different between institution- and home-dwelling older
Finns. The age- and -gender adjusted incidence was markedly higher in institution-
dwellers than home-dwellers (138,142). Furthermore, the gender-specific rates
differed, too. In institutional populations, the age-adjusted incidence rates were equal
for both genders, whereas in community-dwellers, the rate was higher for women
than men (138).
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2.2.1.2 Variation in hip fracture incidence in different countries
Up until the 1980’s to 1990’s, both the absolute number and adjusted incidence of hip
fractures were on the increase in several countries (2,131,145). Thereafter, changes
and different trends in incidence rates have been described. In Norway, hip fracture
incidence has stabilized (130,146,147). A similar phenomenon was observed in
Ontario, Canada, during the 1990’s (148). The age-specific rates of hospital
admissions for femoral fractures in UK and for hip fractures in Australia remained
practically unchanged during the 1990’s (149,150). In northern Spain, the age-
adjusted incidence rates were similar in 1988 and 2002 (151).
   A decline in hip fracture incidence was observed in the early 1990’s in Malmö,
Sweden  (152).  A  similar  trend  break  was  found  for  women  but  not  for  men  in
Östergötland (153). The age-adjusted incidence of hip fractures also decreased in
Swiss women but not in men during the 1990’s (154). The latter reduction was
mainly due to incidence changes in institution-dwelling women (155). In the USA,
the age-adjusted rates of hip fractures showed a declining trend, at least for white
women (156-158). In Denmark, a secular increase in the age-adjusted rates of first hip
fractures was observed until the late 1990’s (159), and a decreasing trend was
described thereafter (160).
   The causes of the observed leveling off and decline in the incidence of hip fracture
are unknown. A combination of period and cohort effects is a possible explanation. In
earlier birth cohorts, the early-life risk factors for fracture, such as nutrition, may have
had stronger impact on the late-life fracture risk than in others (5). The trend break
might also be related to healthier aging and improved functionality among the elderly.
These changes could represent the compression of morbidity, i.e. delayed onset of
disability and reduced proportion of one’s life spent in ill health. Canadian
investigators attributed the decline in hip fracture incidence to implementation of an
osteoporosis screening and treatment program (148). In the Province of Ontario, the
increase in BMD testing was over 10-fold between 1992 and 2001 and the use of
antiresorptive therapy increased nearly 20-fold between 1996 and 2003.
  Upward trends have also been reported in the literature. In Germany between 1995
and 2004, hip fracture incidence increased in older people (161). The increasing trend
was less pronounced for females than males and for western than eastern parts of the
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country. Though the incidence difference diminished between east and west during
the 10-year period, the incidence still remained higher in Western Germany. In Japan,
the age-adjusted incidence of hip fractures increased in both genders between 1986
and 2001 (162). In South Korea, the incidence increased in women aged ? 50 years,
but interestingly, decreased in men during a recent 4-year period (163). In the context
of increasing hip fracture incidence, the authors have pointed to increased life
expectancy and longer survival of the frailest older people due to better medical
treatment, racial factors, level of physical activity and Westernized lifestyle
(161,162,163).
   The occurrence of hip fractures is strongly associated with age, and therefore a
comparison of incidence rates between different populations necessitates the
availability of demographic data and age-specific fracture rates. Bacon et al. studied
hip fracture rates in nine countries (Canada, Chile, Finland, Hong Kong, Scotland,
Sweden, Switzerland, the United States and Venezuela) using national hospital
discharge register data of the years 1988-89 (132). In all nine countries, the hip
fracture rates increased by age and were higher for women than men. The highest
rates were observed in Finland, Scotland and Sweden and the lowest in Venezuela
and Chile. The rates for Venezuela and Chile were three to 11 times lower than those
for the seven other countries. When further adjustments for differences in case
definition were made, the risk of hip fracture was largely similar in the four European
and two North American countries.
   Furthermore, differences in mortality should be taken into account when hip
fracture probabilities are compared. Kanis et al. examined variations in hip fracture
probabilities in 27 countries using incidence data of studies published in the 1990’s
(129). The hip fracture probabilities were computed from the hazard functions of hip
fracture and death, and they were standardized to the probabilities of Sweden (set
1.00). The results are presented in Table 4. The risk of hip fracture varied
considerably. Standardized to the Swedish figures, the 10-year probability of hip
fracture for Norway was 15-times higher than that for Chile.
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Table 4. The ten-year probability of hip fracture averaged for age and gender and
adjusted to the probabilities of Sweden. Adapted from Kanis et al. (129).
Very high risk Medium risk
   Norway 1.24    China, Hong Kong 0.49
   Iceland 1.02    France 0.41
   Sweden 1.0    Japan 0.39
   Denmark 0.85    Spain 0.39
   USA 0.78    Argentina 0.36
High risk    China 0.29
   China, Taiwan 0.72 Low risk
   Germany 0.72    Turkey 0.18
   Switzerland 0.71    South Korea 0.18
   Finland 0.68    Venezuela 0.17
   Greece 0.66    Chile 0.08
   Canada 0.65
   Netherlands 0.64
   Hungary 0.63
   Singapore 0.62
   Italy 0.61
   United Kingdom 0.60
   Kuwait 0.59
   Australia 0.57
   Portugal 0.57
2.2.1.3 Incidence of second hip fractures
The vast majority of older people admitted to a trauma ward, and nearly all of those
admitted with hip fracture, will have sustained a fragility fracture (164), i.e. a fracture
resulting from only low to moderate trauma, usually a fall from standing height or
less. A low trauma fracture is associated with increased risk for subsequent fractures
(165,166), including sequential hip fractures. Several retrospective studies have
reported on the recurrence rate of hip fractures. Among patients with an acute hip
fracture, the prevalence of prior hip fractures ranged between 5.5% and 17% (167-
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174). The majority of these studies focused on non-contemporary bilateral hip
fractures, i.e. subsequent fractures affecting the opposite hip (167-173). Actually,
these data reflect the prevalence rather than the incidence of second hip fractures.
   Prospective population-based studies on epidemiology of second hip fractures are
still relatively few (175-179). In terms of assessing incidence, the methodology of
prospective studies is favorable: follow-up times for second hip fractures are defined
and losses due to death are taken into account. Melton et al. reviewed hip fractures in
Rochester, Minnesota, between 1943 and 1977 (175). In their study, the cumulative
incidence of second hip fractures was 1% at one year after the initial fracture. It rose
to 8% at 5 years, to 16% at 10 years, and finally to 29% at 20 years. A recent study of
Melton et al. covered the years 1980-2006 (179). They reported that the risk of
second hip fracture was 1.7 times greater than that of the first event. Approximately
23% of the second hip fractures occurred during the first year and 70% within five
years following the initial fracture. Furthermore, a downward trend was observed in
the recurrence rate after 1997. A Danish study covering the years 1970-1985 reported
that the mean time between the sequential hip fractures was 3.4 years, and 20% of the
second fractures occurred during the first year and 55% within three years (176).
Compared with the gender-specific risk of first hip fracture, the risk of second hip
fracture was nine times greater for men and 6-fold for women. A later Danish study
reviewed hip fractures in 1994-2004 and found a short time-frame between the first
and second hip fractures (178). The recurrence risk was highest within the first three
months. One half of mens’ second hip fractures occurred during the first year, and for
women the median time was 19 months. After the first year, the risk of second hip
fractures declined to the level of first hip fractures. A recent Japanese study reported
that the incidence increased during the first eight months, it was 3.8% at one year and
decreased linearly during the next two years (177).
   Furthermore, three cohort studies reporting on the incidence of second hip fractures
were found (180-182). In the Longitudinal Study of Aging, the rate of second hip
fractures was one per 33.8 person-years (180). In the Study of Osteoporotic Fractures,
an average annual risk of second hip fracture was 2.3%, and the incidence rate was
four times greater than that of the first hip fractures (181). In the Framingham Study,
the one-year cumulative incidence was 2.5%, and the three- and five-year figures
were 5.7% and 8.2%, respectively (182). Risk factors of second hip fractures are
presented in the chapter 2.2.2.2.
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2.2.2 Risk factors for hip fracture
As with falls, fracture risk in old age is multifactorial. It reflects general frailty, risks
of falling and bone fragility. In a prospective study, 16 factors independently
associated with an increased risk of hip fracture were identified in a cohort of 9 516
community-dwelling older women (183). These factors were: advanced age, history
of maternal hip fracture, weight less than at age of 25 years, tall body height at age
25, fair or poor self-rated health, previous hyperthyroidism, current use of long-acting
benzodiazepines or anticonvulsants, high caffeine intake, being on one’s feet ? 4
hours per day, inability to raise from a chair, impaired depth perception, decreased
contrast sensitivity, tachycardia at rest, any fracture after age of 50 years, and low
bone mineral density (BMD). The effect of most individual risk factors was moderate,
but women with multiple risk factors and low bone density were at especially high
risk. Later on, more independent risk factors have been identified, including female
gender, immobility, sedentary lifestyle, current smoking, low body mass index
(BMI), history of falls, cognitive impairment, low socioeconomic status, and diabetes
(184-191). According to the Scottish guidelines for the prevention and management
of hip fractures (192), the four most prevalent and important risk factors for hip
fracture in older women were:
          1. Previous low trauma fracture after the age of 50
          2. Maternal history of hip fracture
          3. Current smoking
          4. BMI < 18.5
In general, risk factors for falls (Table 1) and osteoporosis (193,194) are closely
related to hip fracture risk. The four easily identifiable shared risk factors for
osteoporosis and hip fractures are listed above. Risk factors are of most importance if
they also are potentially reversible. Shared risk factors for falls and hip fractures
fulfilling these two conditions are e.g. poor visual acuity, use of certain medications,
neurological diseases, abnormality of gait or balance, muscle weakness, arthritis, foot
problems, and environmental hazards (192,195-197). Table  5  shows  the  strong  risk
factors for hip fracture presented in the Finnish current care guidelines for the
treatment of patients with hip fracture.
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Table 5. Hip fracture risk factors with strong (Level A) research based evidence
(198).
Risk Factor
? Previous fall or fracture
? Advanced age
? Impaired mobility and muscle weakness
? Sedentary lifestyle
? Use of assistive device
? Low BMI
? Stroke, Parkinson's disease, Dementia
? Impaired vision
? Use of
o psychotropic drugs
o long-acting benzodiazepines
o antidepressants (SSRI, TCA)
o antipsychotics
The type and severity of falling are crucial in determining whether or not a fracture
occurs (199-201). These factors include for example height, energy, direction, and
mechanism of a fall, anatomical site of the impact, and impact force attenuation by
the body and landing surface. Sideway falls onto the hip were associated to 20 times
higher hip fracture risk than falls in general (200), and these kind of falls were
capable to cause a hip fracture even in young healthy men (202).
2.2.2.1 Medications and hip fracture risk
Psychotropic drugs are associated with an increased risk of hip fracture.
Benzodiazepines in particular have received a great deal of research attention
probably because they are recognized as risk factors for falls and are widely used by
older people. For example in Kuopio, 30% of home-dwelling persons aged ? 75 years
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used one or more benzodiazepine preparations or benzodiazepine like hypnotics in
1998 (203). Based on a review of epidemiological studies, Cumming and Couteur
concluded that use of benzodiazepines increased older people’s hip fracture risk by
50%, and about 10% of hip fractures among community-dwellers were related to
benzodiazepine use (204). The latter percentage (attributable risk) was estimated by
assuming that the prevalence of benzodiazepine use was 20%. The hip fracture risk
was greatest for those who had recently started taking benzodiazepines and for those
receiving higher doses. In addition, the benzodiazepine-like hypnotic zolpidem
increased the fracture risk (205). The effect of elimination half-life on hip fracture
risk is controversial. Ray et al. found short-acting benzodiazepines less harmful (206),
whereas Wagner et al. reported opposite findings (207). In a recent study, daily dose
appeared to be more important factor than the half-life (208).
   The evidence related to antidepressant use and hip fracture risk is less clear than
that on the risk of falls. In an earlier study, TCAs were associated with an increased
risk for hip fracture (209,210). SSRIs were originally thought to be safer. However,
rates of hip fractures were equally high among older women taking SSRIs and those
using TCAs (211). A recent finding is that SSRI use may cause bone loss. Functional
serotonin transporters have been described in osteoblasts, osteoclasts, and osteosytes
(212,213), and serotonin may play a role in bone metabolism. The use of SSRIs has
been associated with a decline in BMD both in men and women (214,215).
   There are a few reports on antipsychotic use and hip fractures, though
antipsychotics may cause extrapyramidal symptoms and impair gait and balance and
thereby contribute to falls. Ray et al. reported that conventional antipsychotics were
associated with a 2-fold increased risk for hip fracture (209), and Liperoti et al. found
that  both  typical  and  atypical  antipsychotics  were  weakly  associated  with  femur
fractures in nursing home residents (216). Antipsychotic use can also disturb bone
metabolism by inducing hyperprolactinemia and secondary hypogonadism. In
patients  with  a  history  of  schizophrenia,  use  of  prolactin-raising  antipsychotics  was
independently associated with an increased hip fracture risk (217).
   Alpha-blockers, used for treating functional symptoms of prostatic hyperplasia and
lowering the risk of urinary retention, may cause hypotension and contribute to
falling and consequent fractures. One study reported that current use of alpha-
blockers was associated with an increased risk of femur fractures (218), whereas
another study found no association (219).
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Long-term use of corticosteroids reduces bone mass, weakens the skeletal
architecture and reduces the biomechanical competence of the skeleton (220). An
increased hip fracture risk related to corticosteroid use has been found in several
studies (220,221). Long-term use of antiepileptic drugs was also associated with
increased rates of bone loss and risk for fractures, especially in women (222,223).
Furthermore, long-term proton pump inhibitor therapy, particular at high doses, can
interfere calcium absorption and may increase hip fracture risk (224,225).
 2.2.2.2 Risk factors for second hip fractures
Compared  to  data  on  risk  factors  for  first  hip  fractures,  less  is  known about  factors
affecting risk for second hip fractures. Egan et al. conducted a systematic review on
factors associated with second hip fractures (226). Older age and cognitive
impairment (227) and lower bone density (181,227) tended to increase the risk of
second hip fracture. Additionally, dizziness and poor or fair self-perceived health
(180), impaired depth perception (181), impaired mobility and previous falls (227)
appeared to increase the risk. Unfortunately, only one (181) of the three studies
quoted above was rated as good in quality in the review article of Egan et al. (226).
   Furthermore, three more recent studies have investigated risks of second hip
fractures. Patients with dementia or Parkinson’s disease showed significantly
increased risk for second hip fracture (177). Greater age independently predicted the
recurrence of hip fracture (179,182), and finally, better functional status was also
associated with an increased recurrence rate (182).
2.2.3 Consequences of hip fractures
2.2.3.1 Morbidity and hospitalizations
Almost all patients with hip fracture are admitted to hospital and the vast majority are
treated surgically (228,229). In Finland, an average total length of hospital stay after
hip fracture was 50 days in 1994-95 according to the national discharge register data
(230). In Central Finland in the late 1990’s , the median length of hospitalization after
hip fracture was 34 days for home-dwelling older people receiving multidisciplinary
geriatric rehabilitation and 42 days for those receiving conventional care (231). In
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Canada and the Netherlands the average period of hospitalization for hip fractures
were 22 and 34 days respectively (232,233). International comparisons regarding the
lengths  of  hospital  stays,  however,  may  be  of  limited  value  because  health  care
systems and care pathways vary from country to country. For example shorter
hospitalization periods may be explained by abundant nursing home use.
   The lengths of stays at the orthopedic wards have shortened substantially during the
past couple of decades in Finland. In Central Finland, the median length of stay after
hip fracture was 18 days in 1982-83 and five days in 1992-93 (231). However, the
proportion  of  patients  discharged  directly  to  their  homes  decreased  and  transfers  to
primary care wards increased concurrently. In South-East Finland the average
perioperative stay was 21 days in 1989 and nine days in 1999 (234,235).
   Rehospitalizations are common among hip fracture patients. Within 30 days
following the initial discharge, 18% of hip fracture patients were readmitted to
hospital (236). Of these 30-day readmissions, 21% were due to diseases of the
respiratory system, 16% related to musculoskeletal and connective tissue diseases and
15%  to  diseases  of  the  circulatory  system.  Several  of  the  comorbidities  that  were
present at the time of initial hospitalization predicted readmissions within 30 days.
Cardiac arrhythmias, chronic pulmonary diseases, and congestive heart failure were
both prevalent and significantly increased the risk for rehospitalizations. The 6-month
readmission rate was 32%, with 8% of the patients readmitted more than once (237).
The majority of these postfracture rehospitalizations (89%) were for nonsurgical
problems, of which infectious (21%) and cardiac (12%) diseases were the most
common.
   Cognitive impairment, depressive symptoms and delirium were also common in hip
fracture patients, and they frequently occurred in combination (238). All three were
independently associated with prolonged hospital stays (239), and they increased risk
for poor outcome, such as institutionalization, death, or permanent decline in
ambulation or ADL functions (238).
   The overall impact of hip fracture on the hospital care utilization was measured in
the Longitudinal Study of Aging (240). The follow-up of the 70+ cohort lasted
approximately for 2.3 years. Hip fracture tripled the likelihood of subsequent
hospitalizations, and the number of hospital episodes increased by 9% and that of
hospital days by 21%.
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2.2.3.2 Mortality
First-year mortality after hip fracture has been reported to range from 14% to 36%
depending on the population studied (241). In Finnish population-based studies, the
overall one-year mortality was 25% in Oulu region between 1989-97 (242), 30% in
Central Finland in 1982-83 and 1992-93 (243), and 32% in the catchment area of the
Kuusankoski Regional Hospital in 1999 (244). The age-specific and age-adjusted
mortality rates remained practically unchanged during the 1980’s and 1990’s
(149,243,245).
   Deaths after hip fracture were related to advanced age, male sex, poor prefracture
health status and postfracture events, such as infections and cardiac complications
(246-253). Causally related deaths, i.e. deaths due to hip fracture, were estimated to
comprise 24 to 70% of deaths in hip fracture patients (254-256), and this fraction
increased with advanced age (254). The vast majority of deaths causally related to the
fracture event occurred in the first postfracture month (257). In death certificates,
however, the hip fracture was relatively seldom assigned as a contributing cause of
death and hardly ever as the first underlying cause of death (258).
   Excess mortality related to hip fractures has been described in several studies
(247,251,252,254,258-264). The majority of excess deaths occurred within the first
three to six months following the fracture. In the first postfracture year, hip fracture
patients’ risk of death was at least twice or three times higher than that of the same-
aged control population (260,261). In women, an increased risk of death persisted for
several years, independently of prefracture health status (259,261,262). In a 12-year
population-based follow-up study, Piirtola et al. found that a hip fracture was a
powerful independent predictor of long-term excess mortality in both genders, and the
risk in men was more than 2-fold that in women (264).
2.2.3.3 Disability, institutionalization, and quality of life
Hip fractures are associated with disability, increased institutionalization rate, and
decreased quality of life. Of those who survived the first postfracture year, half did
not regain prefracture functional status (265). In a US study, 13% of previously
independent persons needed total assistance to ambulate at six months after hip
fracture (266). Nurmi et al. reported that one year after fracturing a hip, the
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proportion of previously independent ambulators had decreased from 59% to 19% ,
and 11% of all hip fracture patients had become bedridden (244). In addition, long-
term difficulties in coping with essential ADLs were observed. One year after hip
fracture,  60%  of  patients  had  still  difficulty  with  at  least  one  basic  ADL,  and  80%
were restricted in instrumental activities, such as driving and grocery shopping (267).
According to Finnish administrative registers, 29% of previously home-dwelling
persons needed long-term institutional care year after hip fracture (268). Similar
institutionalization rates have been reported in other studies (269-272). Furthermore,
a substantial decrease in quality of life has been observed (228,273). Poor
postfracture quality of life was associated with decline in functional status and
persistent hip pain (274).
2.2.3.4 Costs
The average care costs in the first postfracture year were €14,410 per hip fracture
patient according to the 2003 price level in Finland (235). Less than one-fourth of
these costs were caused by acute orthopedic care. If a previously home-dwelling
patient was admitted to long-term institutional care, the average first-year costs rose
to €35,700. In a Belgian study, the first-year costs of hip fracture patients were three
times greater than those resulting from treatment of matched controls without hip
fracture (275). Two-thirds of these excess costs were attributable to nursing home and
rehabilitation  center  stays,  and  one-third  comprised  of  acute  hospitalizations  and
home physiotherapy services. In Italy, the direct costs of hospitalizations for hip
fractures were greater than those for acute myocardial infarcts (276).
   Of the lifetime attributable costs of hip fracture, 33% occurred in the first-half of
postfracture year, and 56% after the first year (277). Even the patients returning to
home after hip fracture have substantial disability resulting from hip fracture. Patients
with new permanent ADL deficits had shorter life expectancy (33% reduction), spent
longer time in nursing home (75% increase) and had multifold care costs compared
with those fully recovered after hip fracture.
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2.3 Prevention strategies of falls and hip fractures
2.3.1 Prevention of falls
The main challenges of fall prevention are to identify persons at risk of falling, find
interventions effective in reducing falls, make these interventions feasible and
attractive for older people, and to do this all cost-effectively. With respect to
identification, the clinical practice guideline for the prevention of falls suggests that
all older persons who are under the care of a health care professional should be asked
about falls at least once a year (49). The guideline also recommends that all who
report a single fall should be tested with “Get Up and Go Test” (278,279), which
involves looking for unsteadiness as the patient gets up from a chair without using his
or her arms, walks a few meters, and returns. Those demonstrating difficulty or
unsteadiness performing this test require further assessment. Above all, high-risk
groups such as older people who present for medical attention because of a fall, report
recurrent falls, or have gait and/or balance problems should have a fall evaluation
performed.
   In addition to “Get Up and Go Test”, other screening tools for identifying people at
risk of falling have also been developed (280-282). However, their predictive value
has been questioned because they may not be optimal for identifying high-risk
individuals for fall prevention, at least in inpatient settings (282,283). Energies may
be more productively directed towards identifying common modifiable risk factors in
all patients and ensuring that people who fall during a hospital stay or are hospitalized
due to a fall-related injury receive a proper post-fall assessment.
   In general, studies on the prevention of falls have two different approaches: a single
intervention strategy (such as exercise or vitamin D) or multiple intervention strategy,
including individually tailored programs (49,113). In a recent Cochrane review,
multidisciplinary and multifactorial risk factor screening and intervention programs
were found to be beneficial both in unselected community-dwellers (4 trials, 1651
participants, pooled risk 0.73, 95% CI 0.63 to 0.85) and in selected high-risk
populations (5 trials, 1176 participants, pooled risk 0.86, 95% CI 0.76 to 0.98) (197).
The meta-analysis of Chang et al. showed that a multifactorial strategy was the most
effective method to prevent falls in older people (284). Similar effectiveness was
found in residential care settings (197) and in psychogeriatric nursing home patients
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(285). On the other hand, less promising conclusions have been drawn as well. Based
on their systematic review and meta-analysis, Gates et al. stated that the evidence of
multifactorial fall prevention programs was limited (286).
   Exercise programs combined with balance training have shown to be effective in
preventing falls. Based on the Cochrane review, muscle strengthening and balance
training reduced falls by 20% (3 trials, 566 participants, pooled risk 0.80, 95% CI
0.66 to 0.98) (197). Similar figures were reported in a more recent meta-analysis, and
programs  that  included  a  combination  of  a  higher  total  dose  of  exercise  and
challenging balance training were found to be most beneficial (287). However, a
recent  review  showed  only  a  vague  effect  of  Tai  Chi  exercise  on  the  risk  of  falls
(288).
   Medication review has been included in the protocol of many multifactorial fall
prevention  studies  (197).  However,  studies  that  specifically  assess  the  effects  of
medication optimization are few. In one study, the risk of falling decreased
significantly after withdrawal of psychotropic drugs, the hazard ratio was 0.34 (95%
CI: 0.16 to 0.74) (289). Despite the fact that the intervention was successful,
permanent withdrawal was difficult to achieve; psychotropics “tended to come back”.
In a more recent study, withdrawal of drugs that predispose to falls appeared to be
effective and profitable both in terms of falling and healthcare costs (290,291). In
addition to psychotropic drugs, review and optimization of cardiovascular drugs was
also beneficial (290,292).
   Vitamin D was not effective in improving strength or physical function or reducing
the risk of falls in older people according to the systematic review performed by
Latham et al. (293). By contrast, a meta-analysis of five randomized controlled trials
(RCT) showed that vitamin D supplementation reduced the risk of falls by more than
20% among ambulatory or institutionalized older individuals with stabile health
(294). Furthermore, there is some evidence that long-term daily supplementation with
800 I.U. of vitamin D combined with 1000 mg of elemental calcium improves muscle
strength and balance control and reduces the number of falls in older community-
dwellers (295).
   Cardiac pacing reduced falls effectively (by 58%) in fallers with cardioinhibitory
carotid sinus hypersensitivity (296). On its part, home hazard assessment and
modification was profitable only for those with a history of falling (197).
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Interventions using cognitive or behavioral approaches alone were not effective, and
thus far, the data on correction of visual deficiency was insufficient (197).
   With regard to older adults’ attitudes and views about fall prevention, relatively
little literature exists. Collectively, these studies suggest that if older adults do not
believe that they are at risk of falling, they are unlikely to take up measures to prevent
falls (297). Especially, those entering old age were not motivated to initiate or
maintain exercise purely to help prevent falls. Nevertheless, strength and balance
training was found necessary and acceptable in the light of wider health benefits and
well-being (298,299).
2.3.2 Prevention of hip fractures
2.3.2.1 Case finding
With respect to case finding, at present there is no universally accepted policy for
population screening in Europe to identify patients with osteoporosis or those at high
risk of fracture (300). Although the diagnosis of osteoporosis relies on the
quantitative measure of BMD, which is a major determinant of bone strength, the
clinical significance of osteoporosis lies in the fractures that arise. Screening for
osteoporosis may be justified because the hip fracture risk more than doubles for
every standard deviation (SD) that bone density decreases (301), and moreover,
almost  all  types  of  factures  have  an  increased  incidence  in  persons  with  low  BMD
(302). However, BMD alone may not be a superior predictor of fracture risk. In the
Study of Osteoporotic Fractures, the proportion of fractures attributable to
osteoporosis (based on a standard definition of osteoporosis: BMD T-score < -2.5
SD) was modest, ranging from 10% to 44% (302). Furthermore, the study group
estimated that less than one third (28%) of female hip fracture cases were attributable
to osteoporosis as defined using total hip BMD. On the other hand, in a large cohort
of community-dwellers aged ? 65 years, screening for osteoporosis (hip BMD) was
associated with 36% fewer incident hip fractures over a six-year period (303). The
mechanism of this association, however, was unclear, the study did not include other
interventions than BMD scans.
   Case finding could be more effective if several risk factors are considered. A novel,
computer-driven fracture risk assessment tool FRAX® has been developed under the
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WHO (304-306). An individual’s risk factors such as age, sex, weight, height, and
femoral neck BMD if available, are entered into the  website tool, followed by
clinical risk factors which include a prior fragility fracture, parental history of hip
fracture, current tobacco smoking, long-term use of glucocorticoids, rheumatoid
arthritis, other causes of secondary osteoporosis and daily alcohol consumption. The
FRAX® algorithm then provides a figure indicating a ten-year probability of any
major osteoporotic fracture and hip fracture. Suggestions for the intervention
threshold and clinical management are also available. As limitations, the FRAX®
assessment tool does not cover risk factors for falls, and it has not been validated by
therapeutic trials in patients selected based on FRAX® scores (306,307).
   Falling is stated to be the strongest single risk factor for hip fractures in older
people (196,201,308). Therefore case finding and prevention strategies should not be
focused on the skeletal risk factors alone. History of falls, gait and balance problems,
and poor vision were found to be significant and independent predictors of hip
fracture (196,198). A simple question about balance can be of value. Self-reported
impaired balance was associated with an almost 4-fold increased risk of incurring a
hip fracture in a cohort of older Swedish twins (309). Approximately 40% of all hip
fractures were attributable to impaired balance in this twin cohort.
2.3.2.2 Fall prevention
There are effective methods for fall prevention, and preventing falls is a logical
strategy to prevent fall-related fractures. But regrettably, no study has had sufficient
power to test this hypothesis (197,310). A fall prevention study large enough for
using fractures as a primary outcome has not been conducted. However, several RCTs
have reported that preventing falls also reduces the number of fractures. A
multifactorial intervention program reduced the number of femoral fractures in
residential care (311), rate of any fractures in older community-dwelling fallers (116),
and subsequent fractures in patients with cervical hip fracture (312). The number of
fractures also decreased in older women who participated in impact exercise (313) or
underwent cataract surgery (314). In these studies, the reduction of fall-induced
fractures was at least 50%. Exercise can reduce bone loss in older age (315), and
multi-component programs including balance, impact and strength training might be
most beneficial regarding prevention of falls and fall-induced fractures (316).
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2.3.2.3 Hip protectors
Since the great majority of hip fractures are caused by a sideway fall with direct
impact on the greater femoral trochanter, injury site protection might be a feasible
fracture prevention strategy. However, the evidence relating to hip protectors is
controversial. Kannus et al. reported very promising results in 2000 (317). In their
RCT, the fracture risk was 60% lower in the hip protector group than in the control
group, and the risk reduction was more than 80% if the protectors were actually worn
at the time of falling. Unfortunately, less encouraging conclusions have been drawn
thereafter. The Cochrane review of hip protectors found some evidence of risk
reduction in institutional settings, but no benefit was found for the majority of older
people living in their own homes (318). No important adverse effects of the hip
protectors were reported but compliance, particularly long term compliance, was
poor. Furthermore, in a multicenter RCT conducted in US nursing homes, no
protective effect was observed despite good adherence to the protocol (319).
However, a recent Japanese study reported that hip protectors reduced the rate of hip
fractures in female nursing home residents with a history of falls and low BMI (320).
2.3.2.4 Calcium and vitamin D
The risk of hip fracture may be reduced by a number of dietary and pharmacological
agents. Calcium plus vitamin D has been shown to significantly reduce the incidence
of all fractures (including hip fractures) in institutionalized elderly women at high risk
for fractures (321,322) and in independently living men and women aged 65 or over
(323). This was also confirmed in the systematic Cochrane review (324). The
evidence on vitamin D alone is less clear, although higher doses (700 to 800 IU/day at
minimum) have been reported to be beneficial (325,326). Calcium alone may not be
effective in preventing hip fractures (327).
2.3.2.5 Bisphosphonates and strontium ranelate
Bisphosphonates act by inhibiting the dynamic resorption of bone by osteoclasts,
reducing the rate of bone turnover, and thereby preserving bone mass. Most of the
studies on bisphosphonates have been designed to test their efficacy on vertebral
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fracture risk, whereas hip fracture risk, if assessed, has been largely considered as a
secondary outcome. Thus far the evidence about effectiveness of bisphosphonates in
preventing hip fractures is scant. Meta-analysis has been used to increase the
statistical power by pooling data from RCTs. A meta-analysis of studies on
alendronate reported that in women with a T-score ? -2.0 SD, or with a vertebral
fracture alendronate therapy reduced hip fracture risk by 45% (95% CI: 16% to 64%)
(328). The risk reduction was greater (55%) for those with a T-score ? -2.5 SD.
Another meta-analysis was based on pooled data of 12 trials (329); bisphosphonates
as a group reduced risk for hip fracture by 42% in postmenopausal women with
osteoporosis or low BMD. The probability that bisphosphonates reduce hip fracture
risk by at least 30% was estimated to be 90%. But still, the evidence is scant in the
groups at greatest risk for hip fracture, i.e. those aged over 75 or 80 years and those
who have already suffered a peripheral fracture including a previous hip fracture
(330).
   The therapeutic mechanism of strontium ranelate is partly different to that of
bisphosphonates. It reduces bone resorption but in addition to that it also stimulates
formation of new bone tissue (331). Hence, it affects both sides of the bone
remodeling imbalance seen in osteoporosis. Strontium ranelate was the only agent
that demonstrated reduction in nonvertebral and hip fracture events in a high risk
elderly female population (332). Over three years, hip fractures occurred in 7.4% of
the women receiving placebo and in 5.2% of women receiving strontium ranelate.
The risk reduction was 32%, however, it did not reach statistical significance
(p=0.112). In a 5-year follow-up, strontium ranelate decreased the risk of hip fracture
by 43% (p=0.036), hip fracture incidence was 7.2% in the treatment group and 10.2%
in the placebo group (333). The finding was based on post hoc analysis of 1128
patients; their mean age was 79.2 SD 4.4 years and mean femoral neck BMD T-score
was -3.6 SD.
   Adherence to osteoporosis medications is often suboptimal, and as could be
expected, this results in a substantial reduction in clinical benefit (334). For example,
43% of 2124 women with postmenopausal osteoporosis remained on bisphosphonate
therapy for one year (335), and in a large database study, only 20% of patients used
bisphosphonates for 2 years (336). Dosing regimen seems to have impact on
adherence: once-weekly dosing was better than daily dosing (337) and once-monthly
regimen may be better than once-weekly (338). Furthermore, a medication
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administered once a year, such as intravenous zolendronate, could improve adherence
to treatment. With regard to secondary prevention of fractures, zoledronic acid
significantly reduced new fractures in patients with hip fracture and improved
survival after hip fracture (339).
   In conclusion, evidence about the efficacy of antiresorptive drug therapy on
reducing hip fracture risk is limited. Most studies of these drugs have been designed
to demonstrate their efficacy on vertebral fracture risk. Adequately sized RCTs
testing their efficacy in preventing hip fractures among older people are rare.
Treatment decisions should be based on sound evidence, i.e. significant reductions in
absolute fracture risk, acceptable NNT (number needed to treat) figures and costs,
rather than reductions in relative fracture risks drawn from re- and post hoc analyses
(310,330, 340).
2.3.2.6 Other medications
Hormone replacement therapy (HRT) has been reported to reduce hip fracture risk by
34-38% (341,342). Due to its negative effects on the risk of breast cancer and
cardiovascular outcomes, HRT is no longer considered an optimal choice for
osteoporosis. Selective estrogen receptor modulator raloxifene has been shown to
reduce vertebral fracture risk, but there is no evidence of its efficacy on hip fractures
or other nonvertebral fractures (343,344).
   The use of thiazide diuretics may protect against age-related bone loss and hip
fracture risk by reducing urinary calcium excretion. Findings of several observational
studies support this hypothesis (345-348). Statin use has also been associated with
lower fracture rates. The mechanism is unclear, but increased bone formation and
BMD as well as better bone health through anti-inflammatory effects have been
hypothesized (349). Bayesian type meta-analysis concluded that there was a 95%
probability that statins reduce hip fracture risk by 27 to 58% (350). In a meta-analysis
of 18 studies, protective effect was found in observational studies, but not in post hoc
analyses of RCTs (351). Heterogeneity and potential residual confounding of
observational studies have been the main sources of criticism (351,352).
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2.3.2.7 Withdrawal of fall-risk-increasing medications
Unfortunately, there is little or no evidence on withdrawal of fall-risk-increasing
medications and fracture risk. One regulatory intervention showed that a statewide
mandatory policy was not profitable in reducing the rate of hip fractures.
Benzodiazepine prescribing policy was tightened up in the New York State, and
consequently the use of benzodiazepines suddenly decreased by more than 50%
among elderly persons (353). Despite of this, the rate of hip fractures did not
decrease. Abrupt discontinuation of long-standing benzodiazepine use may cause
adverse effects, or the benzodiazepines might have been changed to drugs with more
harmful adverse effects (354). In some cases, the use might have continued without
insurance reimbursements. However, the lack of evidence in this field does not mean
that medication optimization is ineffective at preventing hip fractures. Rather it is a
matter of research methodology and resources. Due to the relatively low incidence of
the fracture event, a large sample size and long observation period are required,
equally as in studies on antiresorptive drugs. Furthermore, conducting medication
withdrawal or regimen optimization is a challenging process. The intervention may
need to be individually tailored, and expertise in pharmacology and geriatric medicine
are needed.
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3. AIMS OF THIS THESIS
1. To review and systematically analyze original publications concerning
medications as a risk factor for falls or fall-related fractures.
2. To define characteristics of hip fracture patients and the incidence of hip
fractures, including changes in the incidence within a 10-year period in
Central Finland.
3. To determine the incidence of second hip fractures and describe the
characteristics of patients with two incident hip fractures.
4. To assess  the  effects  of  hip  fractures  on  the  utilization  of  inpatient  care  and
mortality.
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4. MATERIALS AND METHODS
4.1 Methods of the systematic review (Study I)
4.1.1. Literature search
The main data source for this systematic review was the bibliographic database
Medline. The search was limited to English articles published through 1996 to 2004.
Data retrieval with the combination of Medical Subject Headings (MeSH) search
terms “accidental falls” and “pharmaceutical preparations” was performed to find
articles reporting medication use and the risk of falls or fall-related fractures. It
yielded only 20 hits. Combinations of terms "falls" and "medication" or "medicines"
or specific medication groups (benzodiazepines, antidepressants, antipsychotics,
antiepileptics, analgesics, antihypertensive agents, statins, and cholinesterase
inhibitors) gave altogether 673 hits. We also searched the Cochrane library and
examined the reference lists of the retrieved papers.
4.1.2 Study selection
The abstracts of the articles found in the literature search were reviewed, and full text
copies of potentially includable articles were retrieved. Numbers within the square
brackets refers to the reference list of the Study I. A total of 48 original articles [11-
29, 31-59] reporting on an association between medication use and falls or fall-related
fractures were found. Nineteen studies [30-58] were excluded for the following
reasons:
1. Not controlled with non-fallers or -users of the target medication [11-14]
2. Persons aged ? 60 years were included, and results for older persons were not
    reported separately [15-18]
3. Target medications were not defined properly [19-22]
4. The period between medication ascertainment and occurrence of a fall or fall-
    related fracture was longer than one year [23-28]
5. The dropout rate was more than 30% [29]
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4.1.3 Definition and classification of medicines
The Anatomical Therapeutic Chemical (ATC) classification system (355) was applied
to define main groups and subgroups of drugs. In the ATC classification system, the
drugs are divided into 14 main groups according to the organ or system on which they
act, and further divided, into five different levels on the basis of their chemical,
therapeutic and pharmacological properties. According to the ATC classification
system, the main group of central nervous system (CNS) medicines is defined as
including hypnotics, sedatives, anxiolytics, antipsychotics and antidepressants (i.e.
psychotropic drugs), antiepileptics, drugs for Parkinson’s and Alzheimer’s disease,
and opioids.
4.1.4 Statistical methods
The strength of the association between medication use and falls was evaluated using
ORs and 95% CIs reported in the original papers. The results were categorized by
medication groups or by specific medicines reflecting the grade they were reported in
the original papers.
   Furthermore, we performed a meta-analysis of studies evaluating the effects of
psychotropic drug use on the risk of hip fracture. The pooled OR and 95% CIs were
calculated from the raw study data by using the Mantel-Haenszel method (fixed effect
model).
4.2 Methods of the hip fracture studies (II-IV)
4.2.1 Study population
The Central Finland Health Care District consists of 30 municipalities, and 5% of the
Finnish population lives in the area. Patients with hip fracture are referred to the
Central Finland Hospital for surgical assessment, and in this study, hospital registers
and medical records were used to identify hip fracture cases. The residents of the
three southernmost municipalities (Jämsä, Jämsänkoski and Kuhmoinen) can also be
treated in the Jokilaakso Hospital and, therefore, they were excluded from the study.
Thus the study area consisted of 27 municipalities in Central Finland. The total
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population of the area was 239 000, and 21% (50 000) were aged ? 60 years, and 11%
(26 000) 70 or over (356).
4.2.2 Identification of patients with hip fracture
The identification of hip fracture patients was based on registers and medical records
of the Central Finland Hospital. The lists of emergency operations and two electronic
registers were reviewed to detect all the patients who sustained a hip fracture in 2002-
2003. The discharge register was screened using the International Classification of
Diseases tenth revision (ICD-10) diagnostic codes for femur fractures (S72.0 – S72.9)
as  search  terms  (12),  and  the  register  of  the  Department  of  Anesthesiology  was
screened with the surgical codes indicative of treatment of hip or femur fractures.
Medical  records  of  the  identified  patients  were  reviewed,  and  the  residents  of  the
study area with a cervical, trochanteric, or subtrochanteric hip fracture (S72.0-S72.2)
were included in the study (Figure 1). A total of 597 hip fractures in 573 patients
were identified within the two-year period (Table 6).
Figure 1. Anterior view of the proximal femur with regions and codes of hip fractures
by the International Classification of Diseases, 10th Revision (12).
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Table 6. Characteristics of hip fracture patients in 2002-2003 in Central Finland.
Variable Age All
0-49 50-59 60-69 70-79 80-89 90+
Number of patients 20 12 45 182 262 76 597
Number of women, (%) 3 (15) 6 (50) 17 (38) 112 (62) 217 (83) 60 (79) 415 (69.5)
Body mass index (kg/m2), mean (SD) 20.9 (5.6) 25.1 (3.5) 24.3 (3.6) 24.8 (4.4) 23.9 (3.5) 22.9 (3.1) 24.0 (3.1)
Living in institution, number (%) 0 3 (25) 2 (4) 27 (15) 66 (25) 34 (45) 132 (22.1)
Number of comorbidities, median (IQR) 1 (0 , 3) 3 (2 , 3) 2 (2 , 3) 3 (2 , 3) 3 (2 , 3) 2 (2 , 3) 3 (2 , 3)
Hip fracture occurred, number (%)
   Indoors 8 (40) 8 (67) 8 (62) 131 (72) 233 (89) 66 (87) 474 (79.4)
   With a low-energy mechanism 12 (60) 11 (92) 43 (96) 174 (96) 260 (99) 75 (99) 575 (96.3)
   During the night (10pm to 6am) 1 (5) 3 (25) 11 (24) 38 (21) 59 (23) 20 (26) 132 (22)
Fracture type
   Cervical, number (%) 10 (50.0) 9 (75.0) 25 (55.5) 122 (67.0) 161 (61.4) 34 (44.7) 361 (60.5)
   Trochanteric, number (%) 6 (30.0) 2 (16.7) 16 (35.6) 51 (28.0) 77 (29.4) 36 (47.4) 188 (31.5)
   Subtrochanteric, number (%) 4 (20.0) 1 (8.3) 4 (8.9) 9 (5.0) 24 (9.2) 6 (7.9) 48 (8.0)
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4.2.3 Acquisition of baseline data
The following data were retrieved from the hip fracture patients’ medical records:
age, sex, height, weight, place of residence, prefracture morbidity, place of accident,
mechanism of injury, date and time of hip fracture, type of fracture and surgical
treatment, length of stay in the Central Finland Hospital and the discharge destination.
Patients’ prefracture residential status was categorized as follows: home, sheltered
home, nursing home, and long-term hospital care. Care homes and sheltered housing
with 24-hour staff on site were classified as nursing home care. The “round-the-clock
staff on site” criterion was applied to define institutional care, i.e. living in nursing
home or long-term hospital care represented institutional care in this study.
   Prefracture chronic conditions were categorized as follows: dementia, stroke, other
neurological diseases, musculoskeletal diseases, cardiovascular diseases, cancer,
mental disorders, diabetes, pulmonary diseases, and other potentially disabling
chronic conditions. The category of neurological diseases contained conditions
affecting gait and balance such as Parkinson’s and other neurodegenerative diseases,
cerebrovascular and neuroimmunological diseases, epilepsy, polyneuropathy, and
sequelae of brain injuries. The musculoskeletal diseases included conditions likely to
impair mobility, such as arthritis, osteoarthrosis, osteoporosis and sequelae of
injuries. Hypertension, coronary artery disease, valvular and myocardial diseases,
persistent arrhythmias and arteriosclerosis of lower extremities were recorded as
cardiovascular diseases.
4.2.4 Acquisition of follow-up data
The patients were followed up for second hip fractures (Study III). The final day of
follow-up was determined to be one of the following dates (whichever came first): the
date of death, the date of a second hip fracture, or December 31st 2005. Subsequent
hip fractures were identified thorough the hospital registers and medical records,
similarly as the first ones. Only definite new hip fractures were counted as second hip
fractures, readmissions due to complications of the prior hip fracture were excluded.
   Prefracture ambulatory status and the use of medications were recorded for the
patients with two incident hip fractures. The medicines were listed in the emergency
room or ward of trauma surgery, most often by a registered nurse. The information on
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medication use was obtained by patient and/or proxy interview, reviewing
prescriptions and referrals, or contacting referring physicians. Medications were
categorized according to the ATC classification system (355). The number of
regularly taken drugs, use of psychotropic drugs (i.e. benzodiazepines N03AE01 and
N05BA, benzodiazepine-like hypnotics N05CF, antidepressants N06A,
antipsychotics N05A), calcium and vitamin D supplements, and antiresorptive drugs
for osteoporosis (bisphosphonates M05BA and calcitonin H05BA01) were recorded.
Table 7. ICD-10 main classes in Study IV.
Code Disease class
A00-B99 Certain infectious and parasitic diseases
C00-D48 Neoplasms
D50-D89 Diseases of the blood and blood-forming organs and certain disorders
involving the immune mechanism
E00-E90 Endocrine, nutritional and metabolic diseases
F00-F99 Mental and behavioral disorders
G00-G99 Diseases of the nervous system
H00-H59 Diseases of the eye and adnexa
H60-H95 Diseases of the ear and mastoid process
I00-I99 Diseases of the circulatory system
J00-J99 Diseases of the respiratory system
K00-K93 Diseases of the digestive system
L00-L99 Diseases of the skin and subcutaneous tissue
M00-M99 Diseases of the musculoskeletal system and connective tissue
N00-N99 Diseases of the genitourinary system
R00-R99 Symptoms, signs and abnormal clinical and laboratory findings, not
elsewhere classified
S00-T98
   -S00-T14
Injury, poisoning and certain other consequences of external causes
- Injuries
Z00-Z99 Factors influencing health status and contact with health services
Data on hospital days in the 70+ hip fracture patients and general population were
obtained from the nationwide hospital discharge register maintained by the National
Research Centre for Welfare and Health (STAKES). The register covers all inpatient
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care in hospitals and primary care wards. The hospitalization data were categorized
by patients’ age and gender and the ICD-10 diagnostic main classes. The ICD-10
classes are listed in Table 7. Within the diagnostic class of injury, poisoning and
certain other consequences of external causes (ICD-10 codes S00-T98), hospital days
due to injuries (S00-T14) were identified, and more specifically, hospital days
attributable to fall-related injuries. The data acquisition on fall-related hospitalizations
was performed using the following ICD-10 codes: W00-W01 falls on same level,
W10 falls on and from stairs or steps, and W19 unspecified falls.
   To be able to assess the overall incidence of hip fractures, survival and follow-up
time in person-years, data on the population living in the study area and deaths among
hip fracture patients and in the general population were obtained from Statistics
Finland. The study plan was approved by the Ethics Commission of Central Finland
Health Care District.
4.2.4 Statistical analysis
Study II. The patients with hip fracture and the population at risk were stratified by
gender and age (55-64, 65-74, 75-84, 85+), and hip fracture incidence rates with 95%
CIs were calculated. The results were compared with those from 1992-93 (139). To
obtain more detailed information of the oldest old and to improve comparability with
other studies, the present data were also stratified into 10-year age groups, starting
from 50 years and ending at 90+. Standardized estimates of hip fracture incidence rate
ratios (IRR) were calculated by using Poisson regression models or Mantel-Haenszel
combined estimate of the incidence ratio. Statistical significance was evaluated by
using a t-test, analysis of variance (ANOVA), and Cochran-Armitage trend test with
Monte Carlo p-value.
Study III. Results were expressed as means with SDs or medians with range.
Statistical comparison between groups was made by using a t-test, Mann-Whitney
test, or Chi-Square test, when appropriate. Product limit estimation (Kaplan-Meier
method) was used to construct estimated cumulative incidence of second hip
fractures, and 95% CIs were obtained by bias corrected bootstrapping (5000
replications). The factors predicting the second hip fractures were analyzed using
proportional hazard regression models, called Cox’s regression models.
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Study IV. The results were expressed as means or medians with SD or inter-quartile
range (IQR) and 95% CIs. Standardized estimates for count of hospital days and rate
ratios (RR) were calculated using Poisson regression models. The Kaplan-Meier
method was used to calculate and illustrate the cumulative probability of survival.
The gender and age adjusted ratio between the observed and expected numbers of
deaths, the standardized mortality ratio (SMR), was calculated with 95% CIs,
assuming a Poisson distribution.
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5. RESULTS
5.1 Medication as a risk factor for falls: systematic review (Study I)
5.1.1 Design and methods of the reviewed studies
A total of 29 studies [30-58] met the inclusion criteria of the systematic review (Study
I, Table 1). The main objective was to study the association between medication use
and risk of falls or fall-related fractures in 20 studies [31,32,34,35-37,39,41-43,45-
51,54,55,57], whereas the others focused on multiple risk factors for falls
[30,33,38,40,44,52,53,56,58].
   The outcome measure was a fall (single or recurrent) in 17 studies [31-33,35,36,38-
40,44-46,49,50,52,53,55,56], though eight studies did not include a definition of the
term “fall” [31,33,45,48-50,52,55]. Five studies focused on injurious falls
[30,34,54,57,58], six on hip fractures [37,41-43,48,51] and one on femur fractures
[47]. Medicines were defined and categorized according to a systematic classification
system in 11 studies [30,33-36,39,44,53,54-56], whereas more comprehensive and
precise definitions would have been needed in 15 studies addressing several drugs or
drug groups as either targets or potential confounders of  the studies [37,38,40-43,46-
52,57,58]. Confounding factors were often incompletely defined.
   Only one study was a RCT [31]. It concerned risperidone use in nursing home
residents with dementia. Measuring the association between the risperidone use and
incidence  of  falls  was  not  the  primary  objective  of  this  study  but  based  on  the
secondary analysis of the data.
   Of the 28 observational studies, four were cross-sectional [33,36,50,55], nine had
case-control type design [34,37,41-43,47,48,51,54], and 15 were cohort studies
[30,32,35,38-40,44-46,49,52,53,56-58]. The cross-sectional studies were conducted
in community or population-based settings [33,36,50,55]. The information on the
current  drug  use  was  obtained  from  the  participants,  whereas  the  data  on  falls  was
retrospective: the participants were asked to recall whether they had fallen in the
previous 12 months.
In seven of the nine case-control type studies, both the exposure and outcome data
were collected retrospectively [34,37,41,42,47,51,54]. The outcome was defined as an
injurious fall that led to hospital admission, and hospital registers served as data
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sources for case identification. Data on medication use were extracted from
prescription databases, and it was also estimated whether the exposure was current at
the time of the accident. The prospective case-control studies concerned medication
use in patients with hip fracture [43,48]. The data on medication use was collected at
the time of hospital admission for an acute hip fracture, and use of benzodiazepines
was also ascertained by serum analyses.
   Twelve of the 15 cohort studies were prospective [30,32,35,38-40,44,52,53,56-58].
In the five prospective community-based cohort studies, the participants were
contacted at one- to four-month intervals, and the data on falls were collected by fall
calendars [30,44,56] or questionnaires and/or phone calls [35,38]. The data on
medication use was assessed at the baseline only, though the follow-ups lasted from
six to 12 months. In the six prospective cohort studies performed in institutional
settings,  falls  were registered by the staff  of the care facility,  and the potential  time
period between the exposure ascertainment and outcome (drug intake and fall) varied
from one day to one year [32,39,40,52,53,58]. One of these studies utilized a case-
crossover design to test whether adding a new drug to a patient’s medication regimen
may lead to a higher incidence of falls [39]. Furthermore, a large population-based
register study was conducted to examine the incidence of fall-related hospitalizations
within four weeks after a new benzodiazepine prescription [57].
   Three of the cohort studies were retrospective, and they were performed in nursing
home settings [45,46,49]. The data on falls were abstracted from the nursing home
records and the contemporaneous medication use from the medication administration
records or pharmacy reports.
   In  all  the  29  studies,  age  and  gender  (if  both  genders  were  represented)  were
included as potential confounding variables. All 20 studies that primarily focused on
the association between medication use and risk of falls were controlled at least for
one chronic condition [31,32,34,35-37,39,41-43,45-50,51,54,55,57], cognitive
impairment being the one addressed most often [31,32,34,35,39,45-49,51,54,55].
Confounding effects related to concomitantly used medicines were taken into account
in 14 of these 20 studies [31,34,35,37,39,41-43,46,47,49,50,51,57]. Furthermore, the
effects of duration of drug use were evaluated in eight studies
[37,39,41,46,49,51,54,57], and the impact of daily doses in six studies
[31,41,46,47,49,51].
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5.1.2 Psychotropic drugs and falls
5.1.2.1 Benzodiazepines
Benzodiazepines as a group or by certain preparations were evaluated in 22 studies
included in the systematic review [30,32-36,39-44,46-48,50-53]. They were found to
be related to an increased risk of falls in 12 studies
[33,35,36,39,44,46,50,52,53,54,55,57] and to an increased risk of hip fractures in five
studies [41,42,43,47,48]. On the contrary, three studies found no association between
benzodiazepine use and risk of falls [30,40,56], and in two studies the risk increase
was seen only in the initial analyses but not in the final models [32,34]. The results
regarding benzodiazepines are presented more specifically in Study I:  Table 1 and
Figure 1.
5.1.2.2 Antidepressants
Antidepressants were evaluated as a risk factor for falls or fall-related fractures in 20
studies [30,32-35,37-40,42,44,45,49-56]. A statistically significant risk increase was
observed in 10 studies concerning falls [32-35,40,45,49,50,53,55] and three hip
fracture studies [37,42,51]. Furthermore, SSRIs seemed no safer than TCAs in terms
of fall or hip fracture risk (Study 1, Figure 2). On the other hand, the use of
antidepressants was not found to contribute falls in seven studies [30,39,44,52,54,56],
and in one study, they were associated with orthostatic hypotension but not with falls
[38]. Serotonin and noradrenalin reuptake inhibitors (SNRI) were evaluated in one
study only, and no association with falls was reported, OR= 0.97 (95% CI: 0.60 to
1.57).
5.1.2.3 Antipsychotics
Antipsychotics were evaluated in 11 studies. They were associated with increased risk
of falls or injurious falls in five studies [31,32,39,52,54] and with hip fractures in one
study [42]. Additionally, a subgroup analysis showed that antipsychotics contributed
to falls in demented patients living in long-term care facilities [53]. However, in one
community-based study, the relation between antipsychotics and injurious falls was
62
no longer significant after controlling for several confounding factors [34], and in
three studies no association between the drug group and falls was found [30,40,55].
Studies on atypical antipsychotics were rare, and only two studies gave results for
them [31,32]. Neither risperidone nor olanzapine was associated with falls among
persons in geriatric care facilities, though an increasing trend of falls was related to
higher doses of risperidone in the RCT [31], and antipsychotics as a group were
found to be associated with an increased risk in the Swedish study [32].
5.1.3 Other CNS active drugs and falls
Antiepileptics were related to an increased risk of falls in three studies [34,35,44],
whereas one study showed no elevated risk [32]. Cholinesterase inhibitors for
Alzheimer’s disease were evaluated in one study only, and no relation to the risk of
falling was found [32]. Opioids were associated with falls in one study [34], but not
in another [35].
   Use of any psychotropic drug increased the risk of falling in ambulatory nursing
home residents, the incidence density ratio for serious fall-related injuries was 2.49
(95% CI: 1.43 to 4.33) [58]. The use of any CNS active drug was related to the fall
risk elevation in Brazilian community-dwelling older people [50], and in a
population-based sample of older British women [33].
5.1.4 Cardiovascular drugs and falls
Data on the use of other than CNS drugs were collected in 12 studies [30,32-
34,36,38-40,44,53,54,56]. Figure 2 shows the results on the use of cardiovascular
drugs and risk of falling. Three studies reported that cardiovascular drugs were
associated with an increased risk of falling [30,36,56]. Use of antihypertensives
increased risk for injurious falls [30], use of beta-blockers and peripheral
vasodilatators for recurrent falls [36,56], and use of nitrates for any falls [56]. But in
nine studies cardiovascular drugs, as a whole or by examined group, were not
associated with falls [32-34,38-40,44,53,54], and one study reported that the use of
inotropic agents decreased risk of falling [54]. A limitation that should be considered
when interpreting the above studies was that the definitions and groupings of the
63
cardiovascular drugs varied considerably from one study to another, and the results of
risk calculations were not reported in three studies [40,44,53].
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Figure 2. Cardiovascular drugs and risk of falls
5.1.5 Polypharmacy and falls
Polypharmacy was associated with an increased risk of falling in three studies
[33,39,44]. In a nursing home population, the use of five to nine drugs increased the
risk fourfold, and the use of 10 or more drugs up to 5.5-fold compared with the use of
4 or less drugs [39]. Among community-dwelling older people, the use four or more
drugs increased the risk of falling by 30% [44]. However, in older women, the
association with falls was stronger for multiple pathologies than for polypharmacy
[33].
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5.2 Meta-analysis on psychotropic drugs and hip fracture risk
In terms of outcome (hip or femur fracture), seven studies on psychotropic drugs were
potentially includable in the meta-analysis [37,41-43,47,48,51]. All of them were case
control type studies and data for meta-analysis were available. Hubbard et al. reported
on exposure to TCA and SSRI antidepressants in 16 341 hip fracture cases and
29 889 controls [37]. The two studies by Wang et al. concerned the same population:
1 222 hip fracture cases and 4 888 control patients [41,42]. Thus the proportions of
benzodiazepine, antipsychotic and antidepressant users were similar in both of the
studies. Pierfitte et al. reported on the use of benzodiazepines in 245 cases and 817
controls [43], Sgadari et al. in 9 752 cases 38 564 controls, and in the study of
Schwab  et  al.  there  were  82  patients  in  both  of  the  groups  [47,48].  The  use  of
antidepressants was investigated in the large register based study of Liu et al. [51].
The number of hip fracture patients was 8 239 and number of controls was 41 195. In
addition to exposure to antidepressants (SSRIs and TCAs), several other drug groups
were addressed, including anxiolytics. In all of these studies, the controls were age
and gender matched to the hip fracture patients.
Odds Ratio (95% CI)
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Wang [41]
Pierfitte [43]
Sgadari [47]
Schwab [48]
Liu [51]
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Weights, %
   12
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Test for overall effect: 1.94 (95% CI: 1.84 to 2.06), p<0.001
Figure 3. Results of a meta-analysis on benzodiazepines and risk of hip fractures.
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5.2.1 Benzodiazepines and hip fracture risk
For the present meta-analysis, data on the exposure to benzodiazepines were extracted
from five studies [41,43,47,48,51]. The total number of participants was 105 086. The
exposure data based on the history of drug use [43,48] or prescription databases
[41,47,51]. Based on these five studies, use of benzodiazepines was associated with
an increase in the risk of hip fracture, the pooled OR was 1.94 (95% CI: 1.84 to 2.06),
p<0.001 (Figure 3).
5.2.2 Antidepressants and hip fracture risk
Three studies on antidepressants were eligible for meta-analysis [37,41,51]. The total
number of participants was 101 774. Two studies covered both TCAs and SSRIs
[37,51], whereas Wang et al. did not specify types of antidepressants they addressed
[41]. In all studies, both the exposure and outcome data were based on registers.
Meta-analysis of these three studies showed that the use of antidepressants was
related to an increased risk of hip fracture, the pooled OR was 1.82 (95% CI: 1.75 to
1.86), p<0.001 (Figure 4).
Odds Ratio (95% CI)
0,3 0,5 1 1,5 2 3
Test for overall effect: 1.82 (95% CI: 1.75 to 1.86), p<0.001
Antidepressants
Decreased Increased
Wang [41]
Hubbard [37]
Liu [51]
Overall (95% CI)
Weights, %
   64
     4
   32
Figure 4.  Results of a meta-analysis on antidepressants and risk of hip fractures.
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5.3 Incidence of hip fractures (Study II)
5.3.1 Hip fractures in Central Finland in 2002 - 2003
A total of 597 patients were admitted to the Central Finland Hospital for treatment of
an acute hip fracture in 2002-2003. The characteristics of the patients are shown in
Table 6. Patients’ prefracture residential statuses were as follows: 384 (64.3%) were
home-dwelling, 80 (13.4%) were in sheltered housing, 114 (19.1%) lived in nursing
homes and 19 (3.2%) were in long-term hospital care. Thirty-two (5.4%) persons
fractured their hip during acute hospitalization and 10 (1.7%) during short-term
nursing home stay.
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 Figure 5. The percentage of cervical fracture type by age groups in 577 hip fracture
patients. Error bars show the 95% confidence intervals.
A total of 577 (96.7%) patients were aged ? 50 years. The analysis by age groups (50-
59, 60-69, 70-79, 80-89 and 90 years or older) showed that mean BMI decreased
towards the oldest age group (p=0.001), whereas the proportion of institutionalized
patients (p<0.001), low-trauma fractures (p=0.014), and fractures occurring indoors
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(p<0.001) showed monotonic increase with advancing age. The hip fracture type
distribution was the following: 361 (60.5%) cervical, 188 (31.5%) trochanteric and 48
(8.0%) subtrochanteric. The percentage of cervical fractures decreased linearly with
age, p = 0.021 (Figure 5). In the oldest age group, the proportion of the trochanteric
and subtrochanteric fractures exceeded that of the cervical ones (55.3% vs. 44.7%).
  The crude incidence of hip fractures was 3.4 per 1000 py in the 50+ population; 4.5
per 1000 py in women and 2.1 per 1000 py in men. The crude incidence rate ratio
(IRR) between the genders was 2.09 (95% CI: 1.74 to 2.52), and the age-adjusted IRR
was 1.28 (95% CI: 1.07 to 1.55). The incidence of hip fractures increased steeply with
age, being 37.1 (95% CI: 28.3 to 47.8) per 1000 py in women and 35.1 (95% CI: 20.1
to 57.1) per 1000 py in men in the 90+ age group. The gender-specific incidence rates
diverged the most at the age of 80-89 years.
   Through 1992-1993 to 2002-2003, the total number of hip fractures rose by 70%,
from 351 to 597. Four-fifths of the total growth took place in the two oldest age
groups: the increase was 1.7-fold in the age group of 75-84 years and two-fold among
those aged 85 or over (Figure 6).
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Figure 6. Age distribution of patients with hip fracture in 1992-93 (139) and 2002-03.
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5.3.2 Change in the incidence within 10 years
In the female population aged 55 years and over, the hip fracture rate per 1000 py was
3.9 in 1992-1993 and 5.6 in 2002-2003. For the 55+ male population, the incidence
rates were 2.0 and 2.8, respectively. The age-adjusted incidence rate ratios (IRR)
were 1.25 (95% CI: 1.07 to 1.47), p=0.006, and 1.36 (95% CI: 1.06 to 1.76), p=0.017,
for women and men, respectively, indicating that over the decade, the hip fracture
incidence increased statistically significantly in both genders. Further analysis by age
groups (55-64, 65-74, 75-84, and 85+ years) showed that the change was most
marked in men aged 75-84 years, IRR = 1.67 (95% CI: 1.08 to 2.65), whereas in
women the highest IRR, 1.33 (95% CI: 1.02 to 1.75), was seen in the oldest age
group.
5.4 Second hip fractures (Study III)
5.4.1 Incidence of second hip fractures in Central Finland
A total of 501 (70.9% women) persons aged ? 60 years sustained their first hip
fracture in 2002-2003. They were followed up for subsequent hip fractures by the end
of year 2005. The follow-up covered 936 py, and the median follow-up time was 25.5
months. Thirty four (6.8%) persons suffered a second hip fracture and 230 (45.9%)
died during the follow-up. The overall incidence of second hip fractures was 0.036
(95% CI: 0.025 to 0.051) per py. The one-year cumulative incidence of second hip
fractures was 5.1% (95% CI: 3.3 to 7.8), and the two-year rate was 8.1% (95% CI: 5.7
to 11.4). The age-adjusted incidence rate ratio of second hip fractures between men
and  women  was  1.0  (95%  CI:  0.4  to  2.4),  p  =  0.93,  indicating  that  there  was  no
statistically significant gender difference in the incidence rate of second hip fractures.
5.4.2 Risk factors for second hip fractures
The patients’ characteristics collected at the time of first hip fracture are shown in
Table 8. There was no statistically significant difference between the patients with
only one hip fracture and patients who suffered a second hip fracture.
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Table 8. Baseline characteristics of 501 hip fracture patients (age ? 60 years) at the
time of first hip fracture in 2002-2003. The follow-up for subsequent hip fractures
was carried out till the end of the year 2005.
Characteristics Patients with
only one hip
fracture
(n=467)
Patients who
suffered a
second hip
fracture
(n=34)
P-value
   Male / Female 138/329 8/26 0.47
   Mean age, year (SD) 81 (8) 80 (7) 0.91
   Body mass index (kg/m²), mean (SD) 24.2 (3.9) 23.7 (4.3) 0.47
   Living in institution, number (%) 101 (21.6) 6 (17.6) 0.58
 Comorbidity, number (%)
   Dementia 125 (26.8) 9 (26.5) 0.97
   Neurological disease 96 (20.6) 8 (23.5) 0.68
   Musculoskeletal disease 207 (44.3) 12 (35.3) 0.31
   Cardiovascular disease 349 (74.7) 25 (73.5) 0.88
   Cancer 55 (11.8) 2 (5.9) 0.41
   Mental disorder 52 (11.1) 1 (2.9) 0.24
   Diabetes mellitus 73 (15.6) 6 (17.6) 0.76
   Pulmonary disease 65 (13.9) 4 (10.8) 0.72
Type of first hip fracture
   Cervical, number (%)
   Trochanteric, number (%)
   Subtrochanteric, number (%)
277 (59.3)
154 (33.0)
36 (7.7)
27 (79.4)
6 (17.6)
1 (2.9)
    0.074
Bivariate and multivariate analyses were performed to identify potential predictors of
a second hip fracture. Gender, age, BMI, long-term institutional care, any of the
chronic comorbidities or type of first hip fracture did not predict the occurrence of a
second hip fracture (Table 9). The results of the Cox regression models remained
non-significant when the specific comorbid conditions were replaced with the number
of comorbidities (Study III, Table 2).
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Table 9. Cox regression models for potential predictors of a second hip fracture
Predictors Model
Bivariate †
HR (95% CI)
Multivariate
HR (95% CI)
Male gender 0.95 (0.41 to 2.19) 0.88 (0.37 to 2.09)
Mean age 1.01 (0.97 to 1.06) 1.00 (0.96 to 1.05)
Body mass index 0.96 (0.85 to 1.08) 0.95 (0.83 to 1.09)
Living in institution 1.07 (0.44 to 2.60) 1.04 (0.31 to 3.49)
Dementia 1.18 (0.54 to 2.58) 1.16 (0.41 to 3.36)
Neurological disease 1.39 (0.60 to 3.26) 1.19 (0.48 to 2.96)
Musculoskeletal disease 0.57 (0.28 to 1.17) 0.59 (0.27 to 1.28)
Cardiovascular disease 1.08 (0.49 to 2.26) 0.95 (0.40 to 2.23)
Cancer 0.72 (0.17 to 3.02) 0.71 (0.16 to 3.22)
Mental disorder 0.26 (0.03 to 1.98) 0.27 (0.04 to 2.09)
Diabetes mellitus 1.24 (0.51 to 2.99) 1.01 (0.38 to 2.69)
Pulmonary disease 0.91 (0.30 to 2.74) 0.83 (0.28 to 2.49)
Type of first hip fracture
   Cervical
   Trochanteric
   Subtrochanteric
Reference
0.40 (0.16 to 1.00)
0.25 (0.03 to 1.83)
Reference
0.40 (0.16 to 1.01)
0.27 (0.04 to 1.95)
† Adjusted for age and gender.
5.4.3 Medication use in patients with recurrent hip fractures
To assess changes in institutionalization rate, degree of mobility and medication use
between the first and second hip fractures, all patients with recurrent hip fractures
were identified. In 2002-2003, 573 persons experienced 597 hip fractures, thus 24
residents of the study area sustained two incident hip fractures. In addition, 41 of
these 573 persons had experienced one hip fracture prior to 2002 and ten suffered a
second hip fracture by the end of 2005. Thus 75 persons (59 women, 16 men) with
two non-contemporaneous hip fractures were detected. The time between the first and
second hip fracture ranged from 11 days to14 years. The mean age of the patients was
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78 years (range: 46 to 92) at the time of the first hip fracture and 81 (range: 49 to 99)
at the time of the second one.
   Of these 150 hip fractures, 148 (98.7%) were caused by low-energy trauma such as
a fall from a sitting or standing level. Fifty four (72%) of the first and 45 (60%) of the
second hip fractures were cervical. The majority of the second fractures were on the
contralateral side to the first fracture (n=66, 88%).
Table 10. Medication use in 75 patients with two non-contemporaneous hip fractures.
Characteristics At the time of
the first hip
fracture
At the time of
the second
hip fracture
Regularly used drugs, mean (range) 4.4 (0 - 11) 6.5 (0 - 17)
Using daily, n (%)
     0 to 5 drugs
     6 to 9 drugs
     ? 10 drugs
51 (68)
21 (28)
3 (4)
23 (31)
43 (57)
9 (12)
Using daily any psychotropic drug, n (%)
Using daily 2 or more psychotropic drugs, n (%)
Using daily, n (%)
     Benzodiazepine
     Antidepressant
     Antipsychotic
     Benzodiazepine like sleeping pill
27 (36)
12 (16)
14 (19)
14 (19)
7 (9)
8 (11)
44 (59)
23(31)
25 (33)
23 (31)
14 (19)
16 (21)
Using regularly, n (%)
     Calcium and vitamin D
     Bisphosphonates or calcitonin
3 (4)
2 (3)
9 (12)
12 (16)
Between the first and second hip fractures, the proportion of patients in long-term
institutional care increased by 22% from 8/75 to 25/75, and the number of patients
who were able to walk without any aid decreased by 37% from 39 to 11. At the same
time, the mean number of regularly used medicines increased from 4.4 (range 0-11)
to 6.5 (range 0-17), (Table 10). The corresponding figures were 4.2 and 6.0 when the
use of calcium, vitamin D, calcitonin, and bisphosphonates was excluded. Though
psychotropic drugs are associated with increased risk of falling, their use became
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more prevalent between the fractures. The number of patients using one or more
psychotropic drugs daily increased by 23%, from 27 to 44. The relative ratio for
starting the use of a psychotropic drug was 1.63 (95% CI: 1.24 to 2.14) between the
first and second hip fractures. A total of 8/75 (11%) patients had been diagnosed as
having osteoporosis prior to first hip fracture, and at the time of the second hip
fracture, the proportion was 17/75 (23%). None of the patients used the combination
of calcium, vitamin D, and antiresorptive drug at the time of first hip fracture. At the
time of second hip fracture, the combination therapy for osteoporosis was used by
7/75 (9%) patients.
5.5 Utilization of inpatient care before and after hip fracture (Study IV)
5.5.1 Characteristics and treatment of hip fracture patients
A total of 498 (74.9% women) persons aged 70 years or older sustained a hip fracture
in 2002-2003 in the study area. Their mean age was 82 (SD 7) years, and 118 (23.7%)
of them were in long-term institutional care prior to hip fracture. The median number
of prefracture comorbidities was 2 (IQR: 2,  3) in both sexes.  Only one man and 10
women did not have diagnosis of chronic disease. Three-fourths (76%) of the patients
had a cardiovascular disease. Osteoporosis had been diagnosed in 71 (19%) women,
but in only 6 (5%) men. Fifty-three (11%) patients had cancer, and it was active in 13
cases. The prevalence of comorbidities in the 70+ hip fracture patients is presented in
Study 4, Table 1.
   High-energy trauma, such as a traffic accident or falling from a height, caused only
2.2% (n=11) of the hip fractures. The median duration between the occurrence of the
hip fracture and entering the Central Finland Hospital for surgical assessment was
three hours (IQR: 2, 6), whereas the median in-hospital delay to surgical repair of hip
fracture was 27 hours (IQR: 20, 48). Seventeen (3.4%) patients were not operated on,
and the patient’s poor condition was the reason for choosing conservative treatment in
13/17 cases. Twenty-two (4.4%) patients were discharged directly to their homes
from the traumatology ward, 402 (80.7%) patients were transferred to primary care
hospitals and 35 (7.0%) to other institutions. The median length of stay in Central
Finland Hospital was seven days (IQR: 5, 12).
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Figure 7. Mortality after hip fracture in 498 patients aged ? 70 years. Whiskers show
the 95% confidence intervals.
5.5.2 Mortality after hip fracture
A total of 39 (7.8%) patents died during the primary stay in Central Finland Hospital.
The steepest decrease in survival was seen during the first month (Figure 7). The
overall one-month mortality rate was 15.1% (95% CI: 12.2 to 18.5); 13.1% (95% CI:
10.1 to 17.0) in women and 20.8% (95% CI: 14.7 to 29.0) in men.
   At one year after hip fracture, the overall mortality rate was 32.7% (95% CI: 28.6 to
37.0); 29.2% (95% CI: 24.9 to 34.1) in women and 43.2% (95% CI: 35.1 to 52.3) in
men. One-year mortality was significantly higher in the hip fracture group than in the
general population living in the study area, the age- and sex-standardized mortality
ratio (SMR) was 2.9 (95% CI: 2.5 to 3.4). For the female patients the SMR was 2.6
(95 % CI: 2.1 to 3.1), and for the males it was 3.9 (95%: 2.9 to 5.1) (Figure 8). Excess
mortality was seen in all age groups, it increased towards the youngest age group, and
the trend was statistically significant, p<0.001. The overall two-year mortality was
42.0% (95%CI: 37.8 to 46.4); 37.5% (95% CI: 32.8 to 42.7) in women, and 55.2%
(95% CI: 46.7 to 60.0) in men. The two-year SMR was 3.6 (95% CI: 3.1 to 4.0).
74
Age (years)
70-74 75-79 80-84 85-89 90- All
O
bs
er
ve
d 
/ E
xp
ec
te
d
1,0
1,5
2,0
3,0
4,0
6,0
8,0
10,0
15,0
20,0
30,0
Male
Female
Figure 8. Age- and gender-specific one-year mortality rates in patients with hip
fracture (observed death) in relation to death rate in the general population (expected
death) living in Central Finland. The term All indicates the standardized mortality
ratio (SMR) for male and female hip fracture patients aged ? 70 years.
5.5.3 Use of hospital days
In the year preceding hip fracture, hospitalizations among the 498 future hip fracture
patients resulted in 11 458 hospital days, 23 days per py. The number of hospital days
was 40 244 (107 per py) in the first year following hip fracture and 16 242 (52 per py)
during the second postfracture year. In the general population, the number was
constantly 11 per year.
   The age- and gender-adjusted rate ratio (RR) of hospital days per py between the
fracture group and general population was 1.30 (95% CI: 1.27 to 1.32) in the
prefracture year. Men had twice as many hospital days as the 70+ male population,
the age-adjusted RR was 2.07 (95% CI: 1.28 to 3.36), p=0.003, whereas the number
of hospital days in women did not differ from that of the female population, RR =
1.08 (95% CI: 0.58 to 2.02), p=0.80 (Figure 9).
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In the first postfracture year, the age adjusted number of hospital days per py in the
hip fracture group was seven times greater than that of the general population, RR =
6.91 (95% CI: 6.85 to 7.00). The rate ratio of hospital days was higher for men than
women: RR = 9.62 (95%CI: 7.68 to 12.04) vs. RR = 6.22 (95% CI: 4.95 to 7.80). In
the second postfracture year, the RR of hospital days between the fracture group and
population was 3.61 (95% CI: 3.55 to 3.67). The gap between the genders narrowed:
the RR was 4.53 (95% CI: 3.04 to 6.75) for men and 3.04 (95% CI:  2.73 to 4.23) for
women.
Years in relation to hip fracture
-1 to 0 0 to 1 1 to 2
R
at
io
 o
f h
os
pi
ta
l d
ay
s 
pe
r p
er
so
n 
ye
ar
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 Female
Male
Figure 9. Ratio (age adjusted) of hospital days per person-year between the 70-year-
old and older hip fracture patients (n=498) and general population in Central Finland.
The hospital days are for the year before hip fracture (-1 to 0), and for the first (0 to 1)
and second (1 to 2) year after hip fracture. The dotted line shows the hospital days in
the general population and the whiskers the 95% confidence intervals.
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5.5.4 Hospital days by the ICD-10 classes
In the prefracture year, the top three causes for hospital days in the hip fracture group
were  mental  and  behavioral  disorders  (F00-F99),  diseases  of  the  circulatory  system
(I00-I99), and injuries, poisonings and other consequences of external causes (S00-
T98), resulting in 20.7%, 18.9% and 13.9% of all the hospital days, respectively
(Table 11). As could be expected, in the first postfracture year, most hospital days
(54.6%) in the hip fracture group were attributable to the S00-T98 class. In the second
postfracture year, 25.1% of the hospital days were attributable to the F00-F99
diagnoses, 24.5% to the I00-I99 class, and 20.3% to the S00-T98 class. In the general
population, the top three causes for hospital days in all the three follow-up years were
I00-I99 (27.0 - 27.3% of all hospital days), F00-F99 (15.4 - 15.6%), and S00-T98 (8.3
- 8.5%).
   Hospital days due to diseases of the digestive system (K00-K93) and the S00-T98
class were significantly more prevalent in the hip fracture group than in the general
population. The age and gender adjusted RR was 4.03 (95% CI: 1.50 to 10.85) for the
K00-K93 class and 2.03 (1.17 to 3.52) for the S00-T98 class. The RR for the subclass
of injuries (S00-T14) was 2.29 (95% CI: 1.25 to 4.19).
   In the first postfracture year, hospital days attributable to injuries peaked up in the
hip fracture group, and exceeded multifold the days per py in the general population,
RR = 53.69 (95% CI: 38.78 to 74.34). Furthermore, days due to several other
diagnostic classes were also significantly more prevalent in the hip fracture group.
The hospital days per py attributable to the F00-F99, G00-G99, I00-I99, J00-J99,
N00-N99, and Z00-Z99 classes were three to six times more common in the hip
fracture group than in the general population (Table 12).
   In the second postfracture year, excess utilization of inpatient care was still seen in
five diagnostic classes (S00-T98, F00-F99, G00-G99, I00-I99, and J00-99). The
largest  difference  was  in  the  number  of  hospital  days  attributable  to  injuries,  RR  =
8.54 (95% CI: 5.96 to 12.33).
   There were opportunities to identify patients at high risk for hip fracture. As many
as 279 (56.0%) of the future hip fracture patients had been hospitalized during the
prefracture year, and a fall-related injury had been the first underlying diagnosis in 57
cases. In the 70+ population, altogether 810 (3.0%) person required inpatient care due
to injurious falls.
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Table 11. Hospital days by ICD-10 diagnostic classes in the hip fracture group (HF) and in the general population (GP).
ICD-10
class Prefracture year First postfracture year Second postfracture year
HF
n (%)
GP
n (%)
HF
n (%)
GP
n (%)
HF
n (%)
GP
n (%)
All 11 458 304 863 40 244 297 468 16 242 288 012
A00-B99 169 (1.5) 5 647 (1.8) 275 (0.7) 5 443 (1.8) 104 (0.6) 5 333 (1.9)
C00-D48 445 (3.9) 23 472 (7.7) 784 (2.0) 22 942 (7.7) 191 (1.2) 22 140 (7.7)
D50-D89 182 (1.6) 1 785 (0.6) 96 (0.2) 1 749 (0.6) 33 (0.2) 1 719 (0.6)
E00-E90 285 (2.5) 7 609 (2.5) 35 (0.1) 7 532 (2.5) 356 (2.2) 7 455 (2.6)
F00-F99 2 377 (20.7) 46 863 (15.4) 4 550 (11.3) 46 029 (15.5) 4 085 (25.2) 44 924 (15.6)
G00-G99 566 (4.9) 21 614 (7.1) 2 008 (5.0) 21 317 (7.2) 1 613 (9.9) 20 236 (7.0)
H00-H59 14 (0.1) 1 821 (0.6) 14 (0.0) 1 752 (0.6) 3 (0.0) 1 700 (0.6)
H60-H95 7 (0.1) 209 (0.1) 0 (0.0) 196 (0.1) 0 (0.0) 192 (0.1)
I00-I99 2 168 (18.9) 82 291 (27.0) 5 612 (13.9) 80 617 (27.1) 3 980 (24.5) 78 638 (27.3)
J00-J99 916 (8.0) 21 882 (7.2) 2 605 (6.5) 21 365 (7.2) 1 180 (7.3) 20 611 (7.1)
K00-K93 987 (8.6) 9 958 (3.3) 187 (0.5) 9 601 (3.2) 138 (0.9) 9 049 (3.1)
L00-L99 47 (0.4) 1 820 (0.6) 83 (0.2) 1 747 (0.6) 22 (0.1) 1 591 (0.5)
M00-M99 681 (5.9) 18 313 (6.0) 375 (0.9) 17 591 (5.9) 380 (2.3) 17 024 (5.9)
N00-N99 357 (3.1) 10 071 (3.3) 561 (1.4) 9 889 (3.3) 249 (1.5) 9 287 (3.2)
Q00-Q99 0 (0.0) 98 (0.0) 0 (0.0) 98 (0.0) 0 (0.0) 95 (0.1)
R00-R99 514 (4.5) 15 910 (5.2) 239 (0.6) 15 501 (5.2) 257 (1.6) 15 257 (5.3)
S00-T98
S00-T14
1 589 (13.9)
1 578 (13.8)
25 916 (8.5)
21 953 (7.2)
21 980 (54.6)
21 511 (53.4)
24 604 (8.3)
20 817 (7.0)
3 295 (20.3)
3 047 (18.7)
23 834 (8.3)
20 147 (7.0)
Z00-Z99 154 (1.3) 9 584 (3.1) 840 (2.1) 9 496 (3.2) 356 (2.2) 8 927 (3.1)
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Table 12. Hospital days per person-year (py) by ICD-10 diagnostic classes in the hip fracture (HF) group and general population (GP).
Prefracture year First postfracture year Second postfracture yearICD-10
class
Days per
py in HF
group
Days
per py
in GP
RR† (95% CI) Days per
py in HF
group
Days
per py
in GP
RR† (95% CI) Days per
py in HF
group
Days
per py
in GP
RR† (95% CI)
A00-B99 0.25 0.23 1.08 (0.56 to 2.08) 0.59 0.22 2.62 (0.97 to 7.09) 0.26 0.20 1.29 (0.67 to 2.46)
C00-D48 0.86 1.06 0.81 (0.45 to 1.48) 2.11 0.95 2.21 (0.83 to 5.90) 0.61 0.87 0.70 (0.24 to 2.02)
D50-D89 0.26 0.07 3.55 (0.82 to 15.32) 0.16 0.06 2.54 (0.99 to 6.54) 0.07 0.06 1.10 (0.53 to 2.24)
E00-E90 0.35 0.30 1.18 (0.28 to 4.94) 0.07 0.31 0.23 (0.04 to 1.26) 0.97 0.32 3.07 (0.53 to 17.86)
F00-F99 3.09 1.92 1.61 (0.90 to 2.89) 8.63 1.92 4.49 (3.09 to 6.52) 9.56 1.83 5.23 (3.61 to 7.59)
G00-G99 0.98 1.01 0.96 (0.39 to 2.35) 4.83 0.92 5.24 (2.90 to 9.46) 4.53 0.84 5.36 (2.91 to 9.89)
H00-H59 0.02 0.06 0.37 (0.16 to 0.87) 0.03 0.06 0.55 (0.17 to 1.76) 0.01 0.05 0.16 (0.06 to 0.43)
H60-H95 0.01 0.01 1.18 (0.18 to 7.87) 0.00 0.01 0.00 (0.00 to 0.00) 0.00 0.01 0.00 (0.00 to 0.00)
I00-I99 3.48 3.94 0.88 (0.49 to 1.59) 12.90 3.72 3.46 (2.73 to 4.40) 11.30 3.50 3.23 (2.05 to 5.09)
J00-J99 1.65 1.11 1.48 (0.49 to 4.42) 6.95 1.07 6.53 (3.94 to 10.81) 3.88 1.02 3.82 (2.12 to 6.87)
K00-K93 1.75 0.43 4.03 (1.50 to 10.85) 0.41 0.39 1.08 (0.60 to 1.93) 0.37 0.34 1.07 (0.53 to 2.18)
L00-L99 0.09 0.08 1.10 (0.40 to 3.04) 0.21 0.07 3.12 (0.47 to 20.74) 0.07 0.07 1.06 (0.40 to 2.79)
M00-M99 0.96 0.75 1.27 (0.57 to 2.85) 0.71 0.68 1.04 (0.48 to 2.22) 0.87 0.63 1.38 (0.77 to 2.48)
N00-N99 0.53 0.48 1.12 (0.55 to 2.25) 1.24 0.46 2.68 (1.66 to 4.31) 0.65 0.40 1.63 (0.90 to 2.93)
R00-R99 1.00 0.71 1.40 (0.71 to 2.75) 0.49 0.67 0.73 (0.41 to 1.28) 0.66 0.63 0.05 (0.44 to 2.52)
S00-T98
S00-T14
2.42
  2.30
1.19
1.00
2.03 (1.17 to 3.52)
2.29 (1.25 to 4.19)
51.46
   49.77
1.09
0.93
47.05 (35.21 to 62.88)
53.69 (38.78 to 74.34)
8.48
   7.44
1.04
0.87
8.16 (5.94 to 11.21)
8.54 (5.96 to 12.33)
Z00-Z99 0.29 0.47 0.61 (0.34 to 1.11) 2.25 0.43 5.22 (3.68 to 7.41) 1.16 0.40  2.91 (0.99 to 8.57)
† adjusted for age and gender
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6. DISCUSSION
6.1 Medication use and risk of falls
Twenty-eight observational studies and one RCT were included in the systematic
review (Study I). The primary outcome was a fall in 17 studies and a fall-related
injury in 12 studies. Falls were monitored prospectively in 11 studies. A systematic
classification of drugs was used in 11 studies, but still in many studies, drugs or drug
groups were defined incompletely. Duration of therapy was addressed in eight studies
and dosage in six studies. With respect to potential confounding factors, all the
studies were controlled for age and gender. The confounding effect of one or more
chronic conditions was assessed in two-thirds of the studies and concomitant use of
other medications in half of the studies.
   Based on their systematic review of original articles published from 1966 to 3/1996,
Leipzig and colleagues were critical that the evidence linking drugs with falls in older
people was based solely on observational data, with minimal adjustment for
confounders, dosage, or duration of therapy (84,86). Though controlled trials are the
gold standard for identifying the risks associated with drug use, few RCTs have been
conducted  since  the  review  published  by  Leipzig  et  al.  In  this  context,  however,  it
must be noted that controlled clinical trials use often very narrow selection criteria
and may, therefore, underestimate the true prevalence of drug-related adverse events.
Using strict patient selection criteria may also restrict the generalizability of the
findings. Compared to the previous literature (84,86), some improvement in
controlling for confounders was seen in the studies of the present review.
Nevertheless, assessment and control for confounding factors, and confounding by
indication in particular, pose considerable challenges in designing epidemiological
studies and analyzing the data (357). Users of a specific drug are likely to differ from
nonusers, and confounding by indication makes it difficult to ascertain whether the
relationship between falls and medication is due to the actual drug, or the indication
for its use. Despite their limitations, observational studies are often the only option
for assessing drug safety in lager scale, i.e. at population level, among older adults
and in real clinical situations.
   In  the  present  systematic  review,  benzodiazepines  increased  the  risk  of  falling  in
older people. The vast majority of the reviewed studies concerning this drug group
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found  a  small  to  moderate,  but  consistent,  association  between  the  use  of
benzodiazepines and falls. Furthermore, the present meta-analysis showed that the use
of benzodiazepines was also associated with an increased risk of hip fracture.
   Adverse effects of benzodiazepines can contribute to falls in older adults.
Benzodiazepines have negative effects on cognition, reaction time, gait, and balance
(204). Furthermore, pharmacokinetics and -dynamics of these drugs change with age.
The elimination half-life and duration of action is prolonged (83), and the
concentration need to cause sedation decreases substantially with advanced age
(358,359).
   The present findings on benzodiazepines and falls are in concordance with those of
Leipzig et al. (84). Four more recent studies (Table 3) have also reported that
benzodiazepines increase the risk of falling (25,89,91,96). On the other hand,
anxiolytics or hypnotics were not related to falls in three recent studies (93,94,97).
With regard to confounding by indication, Avidan et al. reported that insomnia, but
not hypnotic use, was associated with a greater risk of subsequent falls (94). Their
study was based on a large US nursing home cohort in which the prevalence of
hypnotic use was enviable low, 2.5% (94). Stone et al. measured sleeping time in a
cohort of older women and found that short and fragmented sleep was associated with
falls, independent of benzodiazepine use and other risk factors for falls (360). In these
two studies the follow-up lasted for six to twelve months, but exposure to risks was
assessed at the baseline only. Thus, it was not known whether or not either of the
target variables (insomnia, drug use) was present at the time of falling. Nevertheless,
it is plausible that sleeping problems and daytime tiredness may contribute to falling.
Sleeping pills may offer a temporary relief, but they do not solve the problem, neither
are they effective in long-term use nor free from adverse effects.
   Antidepressant use was related to an increased risk of falls in the systematic review
of Leipzig et al. (84). At that time, only one of the reviewed studies concerned SSRIs
(85). Although it suggested that SSRIs may increase the risk of falls even more than
the tricyclic antidepressants, the possibility of selection bias was speculated, i. e.
SSRIs might have been preferentially prescribed to patients at high risk for falls.
Thereafter several observational studies have reported that SSRIs are associated with
an increased rate of falls (Study I, Figure 2). SSRIs and TCAs have similarities in
their risk profiles through which they can contribute to falling. Both classes increase
serotonin levels and can cause serotonin syndrome when used in higher doses or
81
concomitantly with other serotoninergic drugs (361). They can also provoke
inappropriate antidiuretic hormone secretion and hyponatremia (362,363). Though the
cardiovascular safety of SSRIs is better than that of TCAs (364), SSRIs may exhibit
cardiovascular depressant effects by inhibiting sodium and calcium channels (365).
   With regard to confounding by indication, two observational studies have measured
depressive symptoms at the time of falling, and found that antidepressants, SSRIs in
particular, were independently associated with falls (97) and the association was
stronger for the treatment than disease (366).
   Antidepressants were also associated with a higher rate of hip fractures. In the
present meta-analysis, the pooled risk for hip fractures was 1.82. Besides increasing
the risk of falling, SSRIs may also have negative effects on bone metabolism and
BMD (214,215).
   There is evidence to suggest that antipsychotic drugs may be associated with falls in
older people. Several studies confirming this association were presented in the present
and previous systematic review (84). Older people tend to experience side-effects
from antipsychotics more frequently and with greater severity than younger people,
and drug’s receptor binding characteristics determine largely the side-effects (367).
Extrapyramidal symptoms due to dopaminergic-blocking are important and frequent
adverse  events  of  antipsychotics,  and  frail  older  people  are  more  prone  to  such
complications (368). In addition, antipsychotics have a number of other fall-
contributing adverse effects including sedation, orthostatic hypotension, and
anticholinergic effects such as blurred vision, cognitive impairment, and confusion
(367). New atypical antipsychotics, such as risperidone, quetiapine and olanzapine,
are associated with fewer side-effects, extrapyramidal symptoms in particular, than
typical  antipsychotics  (369).  In  terms  of  falls,  however,  the  documentation  of  their
safety is still vague. Only two studies in the present systematic review concerned new
atypical antipsychotics. Thereafter two studies have reported that new atypical
medications were not associated with fewer falls than the older typical antipsychotics
(25,93). This may be a matter of dosage. With increasing doses, the incidence of
extrapyramidal adverse effects is higher and approaches that of the typical
antipsychotics (368). Unfortunately, the studies referred above did not assess the
impact of dosage on the risk of falling. Hence, further research is needed on the
relative safety of new atypical antipsychotics in older people. Especially, when
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prescribing antipsychotics for behavioral and psychological symptoms of dementia,
physicians need to consider whether the benefits outweigh the risks (93).
   With regard to cardiovascular drugs and falls, the present systematic review does
not provide sound evidence to quid clinical practice. In most of the reviewed studies,
no significant association was found between the use of cardiovascular drugs and
falls. However, this does not mean that assessing an older patient's cardiovascular
medications is unnecessary to prevent falls. On the contrary, in a recent falls
prevention study, the effect of cardiovascular drug optimization was greater than that
of psychotropic drug optimization (290). Especially, fallers with low blood pressure
or orthostatic hypotension need to have a cardiovascular drug assessment.
   Polypharmacy may increase the risk of falls. Leipzig et al. reported that older adults
taking more than three or four medications were at increased risk of recurrent falls
(86). Today's evidence based guidelines recommend several drugs for the treatment of
a single condition, and comorbidity is frequently present as the population is steadily
growing older. Hence, polypharmacy defined as use of more than three or four drugs
covers  nearly  all  our  older  people,  and  does  not  help  to  identify  those  at  risk  of
falling. However, polypharmacy defined as use of six or more drugs and especially
excessive polypharmacy (? 10 drugs) (370,371), can be seen as markers of increased
fall risk. In a nursing home population, polypharmacy and excessive polypharmacy
were associated with a four- to five-times increased risk of falls (372). The
probability of drug interactions increases with an increasing number of medications,
and polypharmacy often involves use of one or more psychotropic drugs (370).
Further, polypharmacy can be a marker of existing but unrecognized health problems,
such as poor disease control, progression of the underlying diseases, or new disease.
6.2 Incidence of hip fractures
In 2002-03, the population of the study area was 239 000 and 597 hip fractures
occurred in the individuals living there. The hip fracture patients were predominantly
women (70%) with a mean age of 82 years. Four fifths of the patients were living in
their own homes or sheltered housing. The vast majority of fractures occurred indoors
(79%), with low-energy mechanism (96%), and between six am and ten pm (78%).
Cervical hip fractures constituted three fifths of all the fracture cases. The hip fracture
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rates  were  higher  for  women  than  men.  This  discrepancy,  however,  was  largely
explained by age; women live longer and reach the “hip fracture age”.
   In Central Finland between the years 1982-83 and 1992-93, the total number of hip
fractures rose by 11% with no significant changes in the age-adjusted or age-specific
hip fracture incidence (139). Between the years 1992-93 and 2002-03, the total
number of hip fractures increased by 70%; for women the increase was 65% and for
men 85%. Also the age-adjusted incidence of hip fractures increased, i.e. the rate was
greater than expected by population aging. In the population aged 55+ years, the
average age-adjusted increase was 36% for men and 25% for women. The gender-
and age-specific changes were the greatest for men aged 75 to 84 years and women
aged 85+ years.
   There was also a small increase in the proportion of trochanteric and
subtrochanteric fractures. Though most fractures still were cervical, their percentage
decreased with age, and among the oldest patients the proportion of trochanteric and
subtrochanteric fractures exceeded that of the cervical fractures. Compared to cervical
hip fractures, trochanteric fractures are associated with more osteoporotic bone
(373,374).
   In the present study and the earlier study by Huusko et al. (139), the incidences
were determined based on two-year hip fracture rates. The methodology of these two
studies is similar and the comparability of findings should be good. These studies,
however, are “cross sectional” rather than incidence trend analyses. Nevertheless, the
age adjusted incidence rate of hip fractures was higher in the later period.
   Kannus et al. have investigated nationwide hip fracture incidence trends in Finland
over a long period of consecutive years (5,137). The incidence showed a steady
increase between 1970 and 1997. In 1998 - 2004, leveling off and signs of declining
incidence trend were observed particularly in women. The exact reasons for the
observed trend break were unknown. The authors discussed that the cohort effect
toward healthier older populations was one possible explanation. An increased
average body weight could also be protective against hip fractures. Since the 1980’s,
BMI and prevalence of obesity have increased in all adult age groups of the Finns
(375). A third possible explanation was improved functional ability of older people
(376) and thereby reduced risk for falling and fractures. Healthier life style, e.g.
exercise and non-smoking policy, may prevent falls and promote bone health. Also
more  specific  actions  to  prevent  and  treat  osteoporosis,  such  as  use  of  calcium,
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vitamin D, HRT and bone-specific antiresorptive drugs, could start to show their
positive effects on the hip fracture risk (5). Last but not least, interventions to prevent
falls, such as strength and balance training, reduction of psychotropic drugs,
correction of visual impairment, modification of environmental hazards and use of
gait stabilizing devices, could have been behind the positive development. The
authors concluded, that the coming years will show whether the favorable trend in the
incidence of hip fractures continues, and even if it does, the absolute number of hip
fractures is still likely to increases because of the population aging.
   In Central Finland, the hip fracture incidence rates have remained high during the
recent years (138), and in 2002-03 the age adjusted incidence still exceeded the 10-
year earlier level. Hence, more efforts are needed to implement and maintain the
preventative strategies and interventions described above.
6.3 Second hip fractures
In order to asses the incidence of second hip fractures, 501 hip fracture patients aged
? 60 years were followed up at least for two years. The rate of second hip fractures
was one per 20 person-years at the end of the first postfracture year and one per 12 py
at two years. The age adjusted incidence of second hip fractures was similar for men
and women. None of the characteristics measured at the time of first hip fracture was
a significant predictor for the subsequent fracture, suggesting that the risk factors for
the first and second hip fractures were largely the same. Even though psychotropic
drugs are known to impair gait and balance and increase the risk of falling and hip
fractures, their use became more common between the first and second hip fractures.
Daily use of any psychotropic drug rose from 36% to 59%, and the concomitant use
of two or more psychotropics doubled.
   The first-year cumulative incidence of second hip fractures was 5.1% in the present
study. Two population-based studies and one cohort study have reported lower rates:
1% (175) 3.8% (177) and 2.5% (182). However, differences in age, mortality and
inclusion criteria may limit direct comparability of the incidence rates. Also secular
changes may affect the incidence if the participants are enrolled over a long period of
time, like in the study of Melton et al. (175) and in the Framingham study (182).
   The present study confirmed the finding that the age adjusted incidence of second
hip fractures is similar for both genders (177,178,179). We did not find predicting
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factors for second hip fractures, but several risk factors have been found in other
studies. Older age, cognitive impairment, lower bone density, impaired depth
perception, impaired mobility, previous falls, dizziness and poor or fair self-perceived
health have been associated with an increased risk for second hip fracture (226). High
functional status has also been reported to be a risk factor for hip fracture recurrence
(182). Better functional status improves survival and recovery after the initial
fracture, but without any interventions, it may also represent increased opportunities
for future falls and fractures.
   The present study evaluated the use of psychotropic drugs, calcium and vitamin D
supplements, and antiresorptive drugs in patients with sequential hip fractures. Use of
psychotropic drugs increased substantially after the initial fracture, whereas
osteoporosis was diagnosed in less than a fifth of the patients and treated even less
frequently. As a limitation, the present study does not provide data on the medication
use in patients who fractured their hips only once. Yet, the treatment of osteoporosis
after hip fracture has been described in other studies. Studies from Canada, US and
Finland reported undertreatment: 18 to 39% of patients received pharmacologic
therapy for osteoporosis after hip fracture (377-379). Thus far, there are no studies on
antiresorptive drugs in secondary prevention of hip fractures, probably because this
kind of study is challenging to conduct. A sample size of 5000 would be needed to
achieve adequate statistical power trial (380) and there might be problems with
placebo controlled design. Zoledronic acid has been studied in 2127 patients with hip
fracture (339). The reduction of second hip fractures was statistically non-significant,
but the rate of new vertebral and peripheral fractures and also mortality decreased
significantly. Good adherence to osteoporosis treatment is important, especially in the
secondary prevention, and once yearly dosing may help to reach this goal.
   The time frame between sequential hip fractures is relatively short. The risk for
second hip fracture is highest within a few months after the initial fracture, and
approximately a half of the fractures occur within one to two years (177,178). Thus,
prevention of a new fracture event has to be started immediately and falls prevention
is of particular importance. Early comprehensive assessment, skilled multidisciplinary
care and rehabilitation, patient centered and individually tailored falls and fracture
prevention, and safe discharge are recommended for the postoperative management
of hip fracture patients (192,198). After hospitalization, continuity of care and
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rehabilitation and long-term follow-up should be ensured. In this context, it means
more than prescription drugs, domestic help, and meals on wheels.
6.4 Mortality after hip fracture
One-third of the ?70-year-old hip fracture patients died during the first postfracture
year. The steepest decrease in survival was seen within the first month following the
fracture. Nearly one-fourth of the first-year deaths occurred during the primary stay in
the  Central  Finland  Hospital.  One-year  mortality  was  three  times  higher  in  the  hip
fracture group than in the same-aged general population. Excess mortality was
highest in the age group of 70-74 years and decreased towards the older age groups.
This may reflect that morbidity differences between hip fracture patients and the
general population were greater in the younger age-groups.
   Huusko et al. reported that the first-year mortality after hip fracture remained
unchanged between the early 1980's and early 1990's (243), neither did it change
during the next decade. Death rates similar to ours have also been reported in the UK;
in Oxford (1984-1998) and in Nottingham (1999-2003) the one-year death rates were
30.7% and 33%, respectively (245,250). The rate was lower, 19% at one year, in a
study including community-dwelling older people only (248).
   Compared with conventional care after hip fracture, better survival and functional
outcome has been gained by centralized geriatric rehabilitation (244,381). Despite of
these encouraging findings, such a care model was not in routine use in the Central
Finland Health Care District. Excluding those who were discharged directly to their
homes or died during their primary stay in the ward of traumatology (n=61), over
90% of the hip fracture patients were transferred to the primary care wards of their
home  municipalities.  Probably  a  part  of  the  early  postoperative  deaths  could  be
prevented by improving the regimens of perioperative care and the availability of
experienced staff, especially during weekends and holidays (382,383).
   The standardized mortality ratio reflects excess mortality in relation to deaths in a
given control population. A previous study with stringent inclusion criteria reported
that hip fractures were not associated with significant excess mortality among patients
older than 85 years when compared with the death rate in the general population
(263). In the present study, the mortality rates in each age group were substantially
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higher among the fracture patients than in the general population. Furthermore, it has
been suggested that otherwise healthy and fit patients do not have increased mortality
subsequent to hip fracture (384), neither do they sustain the fracture frequently; 2% of
our patients had no chronic conditions.
   In conclusion, mortality after hip fracture has remained almost unchanged during
the last 20 years in Central Finland. One-third of older hip fracture patients die within
the first year following the fracture, and nearly a half of the one-year deaths occurred
within the first month postfracture. One-year mortality of hip fracture patients was
three-times that of the same-aged general population. Excess mortality was dependent
on age; it was highest among the youngest hip fracture patients and decreased linearly
with advancing age.
6.5 Hospitalizations after hip fracture
Few studies (240) have addressed the possible impact of hip fracture on the utilization
of inpatient care at a population level. This is probably due to the difficulties in
gaining adequate data on hospitalizations covering entire populations. Fortunately,
the Finnish nationwide hospital discharge register provides sufficiently
comprehensive information on hospital episodes, i.e. the register covers all inpatient
care episodes in hospitals and primary care wards, as well as patient’s age, sex, place
of residence, and the primary cause for hospitalization. In addition, the quality of the
register data is monitored constantly and its validity, preciseness and usefulness for
research purposes are known to be good (385-387).
   In regard to hospitalizations among older people, cardiovascular diseases were the
leading cause for bed days and accounted for one-fourth of all inpatient days in the
70+ population of Central Finland. Mental and behavioral disorders were the second
leading cause and resulted in one of every six hospital days. Injuries, poisonings and
certain other consequences of external causes were the third most important
diagnostic class accounting for one in every 12 bed days. The vast majority of these
days were due to injuries. Thus, measured by hospital days, injuries are a major
public health concern among older people.
   The effects of hip fracture on the utilization of inpatient care were assessed by
evaluating hospital days in the hip fracture group and general population. Hospital
days in the prefracture year were used as a measure of baseline comorbidity. The
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difference in the inpatient care utilization was relatively small in the prefracture year;
the number of age- and gender-adjusted hospital days per person-year was 30%
higher for the future hip fracture patients than for the general population. In the first
postfracture year the number of hospital days was nearly seven times higher in the hip
fracture group than in the general population. In the second postfracture year, it was
still 3.6-fold, despite the fact that the first-year mortality after hip fracture had been
high and presumably concentrated on the frailest patients.
   The utilization of inpatient care was also assessed by specific disease classes. In the
prefracture year, the age-adjusted hospital days per py due to diseases of the digestive
system and injuries were more prevalent in the hip fracture group than in the general
population. It is possible that these conditions could predispose towards hip fracture.
Diseases of the digestive system may cause malnutrition and low body weight, and
previous falls and low-trauma fractures predict future fragility fractures, i.e. low body
weight and a history of osteoporotic fractures are known risk factors for hip fracture
(192, 198).
In the first  postfracture year,  the substantial  excess of hospital  days attributable to
injuries represented predominantly initial hospitalizations for hip fractures. In Finnish
studies, the average length of hospital stay for hip fracture has been six to seven
weeks (230,231). Hospital days in the hip fracture group exceeded the population
levels also in six other ICD-10 classes (Table 12). Rehospitalizations after hip
fracture are common; 18% of patients were readmitted within 30 days after the initial
discharge (236), and at six moths, the readmission rate was 32% (237). Cardiac,
neurological and chronic pulmonary diseases and infections (e.g. pneumonia, sepsis
and urinary tract infections) were among the commonest causes for rehospitalizations
(236,237).
   In the second postfracture year, the days due to injuries were still over-represented
in the hip fracture group. Hip fracture is a significant risk factor for subsequent
fractures (388,389). The risk is highest immediately after the fracture and remains
elevated for a lengthy period. In the second postfracture year, the hospital days due to
mental and behavioral disorders and diseases of the nervous, circulatory and
respiratory systems still exceeded the prefracture and population levels.
   Hence, hip facture was associated to significantly greater use of inpatient care that
persisted at least for two years after the fracture event. An excess of hospital days was
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seen in several diagnostic classes indicating that hip fracture as a major trauma can
exacerbate existing comorbidities and launch a cascade of new impairments.
6.6 Clinical recommendations
More attention should be paid to the prevention of falls and fall-related fractures in
older people. As population-level strategies, strength and balance training, sufficient
intake of calcium and vitamin D, smoking cessation, and injury prevention campaigns
should be promoted. All healthcare professionals who work with older people should
know common risk factors for falls and commit themselves to screen for falls risk, at
least simply by asking about falls. Those at high risk of falling, i.e. older people who
present for medical attention because of a fall, report recurrent falls, or have gait or
balance problems should receive comprehensive evaluation by a clinician with
appropriate skills and experience. Specialist consultations should also be available.
   Medication  review  is  a  part  of  the  falls  risk  assessment.  The  Finnish  Ministry  of
Social  Affairs and Health recommends that every older individual with one or more
chronic conditions have an annual comprehensive medical assessment including
medication review. Falls risk assessment is compatible with this concept. An
assessment must be followed by appropriate interventions. Individually tailored
interventions delivered by a multidisciplinary team of health care professionals have
been shown to be most effective.
   There may be a tendency for physicians and their patients to perceive falls as
secondary and non-medical issues. Overcoming this perception will require a change
of attitudes. Falls in older people should be considered as markers of impaired health
and functional status. Falls can also be drug related adverse events, and they are a
warning sign for impending injuries. To prevent low-trauma fractures, assessment of
osteoporosis risk is needed. The use of the Frax® tool may assist in screening and
clinical decision making. Pharmacotherapy for osteoporosis has its place in the
primary and secondary prevention of fractures, but pharmacotherapy alone is not
sufficient. Pharmacotherapy should be combined with fall prevention strategies. The
majority of peripheral fragility fractures are fall-induced, and fractures may still occur
even though BMD T-scores are above -2.5 SD.
   The high death rate and number of hospital days after hip fracture raise the
question: could we do better? We have a good national practice guideline for
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treatment of patients with hip fracture but the implementation is not sufficient. There
is room for improvement in the perioperative management and postoperative care and
rehabilitation of hip fracture patients. Currently, the postoperative care and
rehabilitation of hip fracture patients is fragmented though these patients are critically
ill and would need special attention. It may be unrealistic to expect that every primary
care ward has the resources and specialist knowledge to treat these high-risk patients.
Centralized, intensive and multidisciplinary postoperative care and rehabilitation
might lead to better results, and even cost-benefits.
6.7 Future research
More information is needed about the effects of medication optimization on the risk
of falls and fall-related fractures in older people. The medication optimization process
should be structured and guided by research evidence or expert consensus statements.
Furthermore, practical tools should be developed to facilitate and improve medication
assessment in clinical practice.
   The methods used in this study for assessing the incidence of hip fractures were
rather laborious. More efforts should be directed towards improving the usability of
routinely collected administrative data on hip fractures. The national discharge
register is a valuable data source for monitoring hip fracture incidence, but further
validation is needed to improve its accuracy and usability. The present incidence data
could be used for such a validation project. Optimally, the impact of falls and fracture
prevention programs could be monitored using register-based data. In addition to hip
fractures, the incidence of other serious fall-related injuries should be easily
monitorable.
   Finally, it seems that our health care policymakers are not yet convinced that
intensive care and rehabilitation of hip fracture patients could lead to better outcomes.
Maybe this concerns also health care professionals. Therefore clinical intervention
studies on the care of hip fracture patients should be promoted. These studies may
investigate which patients benefit the most and what are the specific components and
exact contents of successful rehabilitation. Clinical feasibility and implementability
should be of special interest when designing intervention studies. Proper post-
intervention follow-up and cost analysis should be promoted as well.
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7. CONCLUSIONS
1. The systematic review of recently published studies showed that the current
evidence on medication use and risk of falls is mainly based on observational
studies, and many of them have methodological deficiencies. More randomized
controlled trials are needed, and falls as an adverse effect should be included in
the protocol of the clinical trials of medicines intended for elderly persons. CNS
medicines, especially psychotropic drugs, are associated with an increased risk
of falls in older people. In particular, the use of benzodiazepines or
antidepressants, including SSRIs, was consistently associated with an increased
risk of falls in older people. These drugs were also associated with a nearly two-
fold risk for hip fracture.
2. The majority of patients with hip fracture were community-dwelling older
women, and most of the hip fractures occurred indoors with a low-energy trauma
mechanism, such as a fall on same level. The location of fracture was cervical in
most cases, but the proportion of trochanteric and subtrochanteric hip fractures
increased with age and exceeded that of the cervical fractures in the oldest old.
The number of hip fractures almost doubled in Central Finland between the
years 1992-93 and 2002-03. The incidence of hip fractures increased in both
genders, and the accretion was more than could be explained merely by
demographic changes.
3. The recurrence rate of hip fractures was rather high. The cumulative incidence of
second hip fractures was 5% at one year after the initial fracture and 8% at two
years. Among patients with sequential hip fractures, psychotropic drugs were
commonly used even though they are known to impair gait and balance control
and increase the risk of falling and fall-related fractures. The use of
psychotropics increased after the first hip fracture. In contrast, the use of
calcium, vitamin D and antiresorptive drugs was often overlooked in these high
risk patients.
4. Mortality after hip fracture was high. One third of ?70-year-old hip fracture
patients died within the first year following hip fracture. The death rate was
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three-fold  that  of  the  same-aged  general  population.  At  two  years  after  hip
fracture the overall mortality was 42%, and as high as 55% in the male patients.
The evaluation of hospitalizations in the 70+ population showed that hip
fractures were also associated with a substantial increase in the utilization of
inpatient care. Hospital days in several diagnostic classes increased and still
exceeded both the prefracture and population levels in the second postfracture
year. A hip fracture can far exceed the restricted reserve capacity of an older
person and predispose to worsening of pre-existing comorbidities and the onset
of new diseases.
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8. SUMMARY IN FINNISH – SUOMENKIELINEN YHTEENVETO
Tutkimuksen lähtökohdat
Suurin osa ikääntyneiden tapaturmista syntyy kaatumisen seurauksena. Noin
kolmannes kotona asuvista ja yli puolet laitoksissa asuvista yli 65-vuotiaista kaatuu
vuosittain ainakin kerran.  Kaatumisille altistavat monet ikääntymiseen ja sairauksiin
liittyvät tekijät. Myös lääkkeiden aiheuttamat haitat voivat lisätä kaatumisvaaraa.
   Kaatumisvammoista vakavimpia ovat reisiluun yläosan murtumat. Lonkkamurtumat
lisäävät sairastavuutta ja kuolleisuutta sekä aiheuttavat toimintakyvyn laskua.
Murtuman hoidosta ja toimintakyvyn heikkenemisestä aiheutuvat kustannukset ovat
myös merkittäviä. Lonkkamurtumien ilmaantuvuus nousee iän myötä, joten väestön
vanhetessa kaatumisten ja kaatumisiin liittyvien murtumien ehkäisyn merkitys
korostuu entisestään.
Tavoitteet
Tämä väitöskirjatyö koostuu systemaattisesta kirjallisuuskatsauksesta ja
lonkkmurtumien epidemiologiaa käsittelevästä väestötason tutkimuksesta.
Systemaattisessa kirjallisuuskatsauksessa selvitettiin lääkkeiden käytön ja
kaatumisten sekä lonkkamurtumien välistä yhteyttä ikääntyneillä ihmisillä.
Epidemiologisen tutkimuksen tavoitteena oli lonkkamurtumien
kokonaisilmaantuvuuden ja lonkan uusintamurtumien ilmaantuvuuden määrittäminen
sekä lonkkamurtumien jälkeisen sairaalahoidon käytön ja kuolleisuuden selvittäminen
keskisuomalaisessa väestössä.
Menetelmät
Lääkkeitä kaatumisten ja lonkkamurtumien vaaratekijöinä selvittäneen systemaattisen
katsauksen kirjallisuushaku koski vuosina 1996-2004 julkaistuja englanninkielisiä
alkuperäistutkimuksia. Valintakriteerit täyttäneet artikkelit analysoitiin
tutkimuspopulaation, -asetelman, käytettyjen metodien, kohdelääkkeiden ja tulosten
suhteen. Lonkkamurtumien ja bentsodiatsepiinien sekä masennuslääkkeiden käytön
välistä yhteyttä selvittäneistä tutkimuksista tehtiin meta-analyysi.
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   Epidemiologinen työ koski Keski-Suomessa vuosina 2002 ja 2003 sattuneita
lonkkamurtumia. Lonkkamurtumapotilaiden tunnistamiseen käytettiin Keski-Suomen
keskussairaalan hoitojaksorekisteriä, leikkausyksikön tietokantaa ja
päivystysleikkauslistoja. Lonkkamurtumadiagnoosin oikeellisuus ja murtumatyyppi
varmistettiin sekä kliiniset tiedot kerättiin potilaiden sairauskertomuksista.
Lonkkamurtumiksi luettiin reisiluun kaulan ja trokanteerisen sekä subtrokanteerisen
alueen murtumat.
   Potilaita seurattiin kuolemantapausten ja lonkan uusintamurtumien suhteen vuoden
2005 loppuun. Uusintamurtumapotilaiden ensimmäistä ja toista lonkkamurtumaa
edeltävä lääkehoito kartoitettiin poikkileikkaustyyppisesti. Lonkkamurtumapotilaiden
ja alueen väestön sairaalahoitopäivien käyttö ja hoitojaksojen päädiagnoosiryhmät
selvitettiin valtakunnallisesta hoitoilmoitusrekisteristä.
Tulokset
Systemaattinen katsaus käsitti 29 alkuperäistutkimusta, joista vain yksi perustui
satunnaistettuun ja kontrolloituun tutkimusasetelmaan. Tutkimusmenetelmissä ja
sekoittavien tekijöiden hallinnassa todettiin puutteita, joskin ne olivat vähäisempiä
kuin aiempaa kirjallisuutta analysoineessa katsauksessa oli havaittu. Useissa
tutkimuksissa todettiin psyykenlääkkeiden käytön ja kaatumisvaaraan välinen yhteys.
Yhtenäisintä tutkimusnäyttö oli bentsodiatsepiinien ja masennuslääkkeiden osalta.
Kaatumisten suhteen SSRI-ryhmän masennuslääkkeet eivät osoittautuneet trisyklisiä
valmisteita turvallisemmiksi. Lonkkamurtumat olivat bentsodiatsepiinien ja
masennuslääkkeiden käyttäjillä lähes kaksi kertaa yleisempiä kuin näitä lääkkeitä
käyttämättömillä ikääntyneillä henkilöillä.
   Vuosina 2002-2003 keskisuomalaisessa väestössä sattui 597 lonkkamurtumaa.
Murtumien kokonaismäärä nousi 70 %:lla kymmenen vuoden takaiseen tilanteeseen
nähden. Myös lonkkamurtumien ikävakioitu ilmaantuvuus suureni molemmilla
sukupuolilla. Tyypillinen lonkkamurtumapotilas oli yli 80-vuotias kotona asuva
nainen, ja yleisin lonkkamurtumaan johtava vammamekanismi oli kaatuminen
sisätiloissa.
   Lonkan uusintamurtumien kumulatiivinen ilmaantuvuus oli 5 % vuoden ja 8 %
kahden vuoden kuluttua ensimmäisestä lonkkamurtumasta. Ensimmäisen murtuman
yhteydessä määritetyistä muuttujista ei löytynyt toista lonkkamurtumaa ennustavia
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tekijöitä. Samat vaaratekijät saattoivat näin ollen vaikuttaa sekä ensimmäisen että
toisen lonkkamurtuman syntyyn. Psyykenlääkkeiden käyttö kuitenkin yleistyi
ensimmäisen lonkamurtuman jälkeen. Ensimmäisen lonkkamurtuman aikaan 36 %
potilaista käytti jotain psyykenlääkettä. Toisen murtuman aikaan käyttäjiä oli 59 %.
Bentsodiatsepiinit olivat yleisimmin käytetty psyykenlääkeryhmä.
Osteoporoosilääkkeen, kalkin ja D-vitamiinin yhdistelmää toisen lonkkamurtuman
saaneista potilaista käytti 9 %.
   Yli 70-vuotiaiden lonkkamurtumapotilaiden kuolleisuus oli korkea. Kuukauden
kuluttua lonkkamurtumasta 15 % potilaista oli kuollut ja vuoden kohdalla kuolleisuus
oli 33 %. Murtumapotilaiden kuolleisuus oli kolminkertainen alueen samanikäisen
väestön kuolleisuuteen verrattuna.
   Murtumaa edeltävänä vuotena tulevat lonkkamurtumapotilaat käyttivät
sairaalahoitopäiviä 30 % enemmän kuin samanikäinen väestö. Ensimmäisenä
lonkkamurtuman jälkeisenä vuotena ero oli seitsenkertainen. Toisena
lonkkamurtuman jälkeisenä vuotena lonkkamurtumapoilaiden hoitopäivien määrä oli
yli kolminkertainen väestöön nähden. Tapaturmasta johtuvien hoitopäivien lisäksi
usean muun sairausryhmän hoitopäivät ylittivät väestön hoitopäivien käytön sekä
ensimmäisenä että toisena murtuman jälkeisenä vuotena.
Päätelmät
Lonkkamurtuma on vakava tapaturma, joka usein ylittää ikääntyneen ihmisen
reservikapasiteetin ja lisää sairastavuutta sekä kuolleisuutta merkittävästi. Aiemmista
tutkimuksista tiedetään, että lonkkamurtumapotilaiden ennustetta voidaan parantaa
tehostetulla ja keskitetysti toteutetulla moniammatillisella hoidolla ja kuntoutuksella,
vieläpä lisäämättä hoidosta koituvia kokonaiskustannuksia. Hajautetun hoidon malli
oli kuitenkin edelleen vallitseva. Lyhyen perioperatiivisen hoitojakson jälkeen
potilaat siirrettiin kotipaikkakuntiensa terveyskeskusten vuodeosastoille.
Lonkkamurtumapotilaiden hoidossa ja kuntoutuksessa on parantamisen varaa.
Murtumien ehkäisyä ajatellen kaatumisvaarassa olevien ikääntyneiden tunnistaminen
ja aktiivinen vaaratekijöihin puuttuminen ovat avainasemassa. Säännöllinen
lääkityksen arviointi on tärkeä osa tätä prosessia.
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